Abstract: Voltage-gated sodium channels (Na\textsubscript{V}s) are a key determinant of neuronal signalling. Neurotoxins from diverse taxa that selectively activate or inhibit Na\textsubscript{V} channels have helped unravel the role of Na\textsubscript{V} channels in diseases, including chronic pain. Spider venoms contain the most diverse array of inhibitor cystine knot (ICK) toxins (knottins). This review provides an overview on how spider knottins modulate Na\textsubscript{V} channels and describes the structural features and molecular determinants that influence their affinity and subtype selectivity. Genetic and functional evidence support a major involvement of Na\textsubscript{V} subtypes in various chronic pain conditions. The exquisite inhibitory properties of spider knottins over key Na\textsubscript{V} subtypes make them the best venom peptide leads for the development of novel analgesics to treat chronic pain.

Keywords: chronic pain; ICK peptide; knottins; Na\textsubscript{V}; spider venom; voltage-gated sodium channel

Key Contribution: Spider venoms are a rich source of Na\textsubscript{V}-modulating knottins. This review discusses how spider knottins modulate Na\textsubscript{V} channels, the structural determinants that define their affinity, potency and subtype selectivity and their potential to target Na\textsubscript{V} subtypes involved in chronic pain conditions.

1. Introduction

Spiders are considered the most speciose and successful terrestrial venomous predators [1]. They comprise 119 families, 4141 genera and 48,255 species at the time of writing [2], with over 150,000 species estimated to exist [3,4]. They form the seventh most diverse order Araneae and completely rely on predation [3,5]. Their venoms comprise highly evolved venom peptides that facilitate both predatory behaviour by killing or paralysing the prey and defence against predation [6]. Medically significant cases of spider envenomation are less common and usually associated with intrusion in the spider’s natural habitat or threatening encounters [7]. Spider venoms are highly specialized in targeting the molecular receptors, especially the neuronal system, of insects to immobilize or kill their preys. However, their venoms also impart noxious effects to higher organisms such as mammals. The conserved structure and function of targeted receptors from evolutionarily distant prey species, such as insects and threatening species, including mammals, likely explains the ability of spider venom peptides to potently modulate human receptors [8,9].

Recent advances in analytical technologies have made comprehensive biochemical and functional investigations of spider venoms feasible [10]. In addition, high-throughput technologies, such as fluorescence imaging and automated electrophysiology, have sped up the screening and discovery
of novel bioactive venom peptides. Chemically, spider venoms comprise a highly complex cocktail of enzymatic and non-enzymatic protein and peptide toxins and low molecular weight organic compounds, such as nucleotides, free amino acids, biogenic amines, neurotransmitters, acylpolyamines, inorganic ions and salts [11–13]. Spider venom peptides modulate an array of ion channels and receptor proteins, including transient receptor potential (TRP) channels, acid sensing ion channels (ASICs), mechanosensitive ion channels (MSICs), ionotropic glutamate receptors (GluRs), G-protein coupled receptors (GPCRs), voltage-gated sodium (Nav) channels, voltage-gated potassium (Kv) channels, voltage-gated calcium (CaV) channels and calcium-activated potassium channels (KCa) [4,14]. Interestingly, approximately one-third of the then described spider venom ion channel modulators targeted NaV channels [15].

Venom peptides from spiders have been important tools in defining the function and pharmacology of NaV channels and in elucidating binding sites in these channels [16–18]. For example, the hNav activator spider knottin Hm1a from Heteroscodra maculata recently elucidated the role of Nav1.1 in mechanical hypersensitivity and chronic visceral pain [19,20], while other Nav inhibitor spider knottins continue to be developed as novel analgesics [21]. Thus, spider venoms provide a rich source of bioactive peptides to probe the function and pharmacology of NaV channels as well as being leads to new therapeutics. In this review, we provide an overview of spider knottin pharmacology at NaV channels, describe the structural determinants driving their potency and selectivity and discuss the potential of spider knottins to target NaV subtypes involved in chronic pain conditions.

2. Voltage-Gated Sodium Channel Function and Structure

Voltage-gated sodium channels (Nav1.1–1.9) are transmembrane channel proteins selective to Na+ ions. They open upon depolarization of the membrane to allow the influx of Na+ ions and inactivate rapidly through a process named fast inactivation before returning to the closed state upon membrane hyperpolarization. Such rapid influx of Na+ ions is key to generation and propagation of action potential and underlies transmission of a wide array of somatosensory signals, including touch, smell, temperature, proprioception and pain [21]. A range of molecules discovered from natural sources (e.g., venomous animals) interact with NaV channels to activate or inhibit the influx of Na+ ions [16,22]. NaV channels are also expressed in non-excitable cells where they contribute to non-canonical functions [23], such as catecholamine release [24], angiogenesis [25], phagocytosis, endosomal acidification and podosome formation [26,27], production of pro-inflammatory mediators [28] and are key regulators in various human pathologies, such as cancer progression [29], multiple sclerosis [30], epilepsy [31] and pain syndromes [32,33]. In addition, mutations of Nav channel-encoding genes contribute to diseases such as epilepsy, pain-related syndromes (e.g., inherited primary erythromelalgia (IEM), congenital insensitivity to pain (CIP) and paroxysmal extreme pain disorder (PEPD)) and cardiac arrhythmias, such as Brugada syndrome, atrial fibrillation and slow ventricular conduction [34–38].

Structurally, eukaryotic Nav channels are complex transmembrane glycosylated proteins composed of a large pore-forming core protein (α-subunit, approximately 260 kDa) associated with one or more regulatory proteins (β-subunits, approximately 35 kDa) [39]. The α-subunit is primarily involved in Na+ conductance, whereas β-subunits modulate the Na+ current kinetics and α-subunit expression [40]. Four regulatory β-subunits (β1–β4) have been identified so far with a soluble splice variant β1B [41]. The β1 and β3 subunits make non-covalent interactions, while the β2 and β4 subunits make covalent interactions with the α-subunit to form a heteromeric protein [42].

The α-subunit comprises 24 transmembrane segments organized into four homologous, non-identical domains DI–DIV, each containing six transmembrane segments S1–S6 (Figure 1A,B) [43–45]. The S1–S4 segments of each domain contribute to the voltage sensing domain (VSD), and the S5 and S6 segments along with the extracellular connecting loop (P-loop) form the pore domain (PD) and selectivity filter. Conserved positively charged residues (arginine) at every third position in the S4 segment sense voltage changes across the membrane and regulate the gating kinetics of the NaV channel [46] through a “sliding helix” or “helical screw” mechanism [47–49]. At resting membrane potentials, the S4 segments (voltage
sensors) are drawn into the membrane where their positively charged residues form ion pairs with negatively charged adjacent residues from S1, S2 and/or S3 segments [50]. However, when the negative membrane potential becomes more positive during membrane depolarization, the S4 segments of DI–DIII move outward, resulting in a conformational change that opens the channel pore followed by the outward movement of DIV S4 that inactivates (blocks) the channel pore intracellularly [50,51]. Channel inactivation is the third cardinal feature of Na\(^+\) channels in addition to voltage sensing across the membrane and the selective Na\(^+\) filter [52]. Structurally, the cytoplasmic DIII–DIV linker forms a hinge that facilitates the inactivation and is key to the fast inactivation mechanism. A cluster of hydrophobic amino acids (i.e., Ile, Phe, and Met (IFM motif)) function as a hydrophobic latch to stabilize the inactivated state, and mutations in these residues individually and together alter the kinetics of fast inactivation [53]. Besides this motif, residues in the S4–S5 linkers of DIII (e.g., A1329) and DIV (e.g., N1662) are crucial for the fast inactivation as they form the docking site for IFM motif [54].

![Figure 1](image-url)
Although the Na$^+$ channel gating has multiple kinetic states [59,60], it can be simplified into three distinct physiological states, the resting (closed), open, and inactivated, which develop from the voltage-sensitive conformational changes that occur within the $\alpha$-subunit (Figure 1C) [57,61]. Toxins and drugs that interact with Na$^+$ channels often bind preferentially to one of these conformational states to alter Na$^+$ conductance or the gating properties of the channel. Six neurotoxin receptor sites (Sites 1–6) have been identified on the Na$^+$ channel. Site 1 neurotoxin physically occludes the channel pore, whereas neurotoxins acting at Sites 2–6 affect the gating mechanisms of the channel. Venom peptides target four neurotoxin receptor sites in human Na$^+$ channels, namely, Site 1 (e.g., $\mu$-conotoxins), Site 3 (e.g., scorpion $\alpha$-toxins, sea anemone toxins and spider toxins), Site 4 (e.g., scorpion $\beta$-toxins, spider toxins) and Site 6 (e.g., $\delta$-conotoxins) [16,62]. Given their physico-chemical properties, it is not surprising that Na$^+$ modulatory venom peptides preferentially target the extracellular side of VSDII (Site 4) and VSDIV (Site 3) [14,63].

3. Spider-Venom ICK Peptides

Inhibitor cystine knot (ICK) peptides have a disulphide-rich structural motif that forms a “knot” that confers high structural, thermal and proteolytic stability, making them attractive starting points for structure–function studies and clinical lead development [64]. This structural motif comprises at least three disulphide bonds with connections between C1–C4, C2–C5 and C3–C6, where two disulphide bonds form a ring threaded by the third (C3–C6) disulphide bond to form the knot. These scaffolds were first described as “knottins” in 1980s [65] and later identified as a “cystine knot” in the crystal structure of nerve growth factor [66,67]. Pallaghy et al. [68], in 1994, coined the term “inhibitor cystine knot” to identify the cystine knot motif with a triple-stranded anti-parallel $\beta$-sheet topology. Craik et al. [69] further categorized these disulphide-rich structural motifs as (i) growth factor cystine knots (GFCKs), (ii) inhibitor cystine knots (ICKs) and (iii) cyclic cystine knots (CCKs). ICKs and CCKs have the same disulphide connectivity, but the disulphide connectivity in GFCK differs where C1–C2 threads the ring formed by C2–C4 and C3–C6. ICKs and CCKs are referred to as knottins and cyclotides, respectively [70]. Animal toxin cystine knots have an ICK structural motif [69].

Spider venoms are a rich source of disulphide-rich peptides, including knottins [4]. With few exceptions, such as the atracotoxins, they display the ICK features comprising three disulphide bonds (Figure 2A). However, certain variations are observed within the $\beta$-sheet topology (Figure 2B,C). Unlike the triple-stranded anti-parallel $\beta$-sheet topology defined in knottins, spider venom knottnins typically comprise two $\beta$-strands with a few exceptions displaying a third strand at the N-terminal [71]. Besides the disulphide bridge connectivity, another conserved structural feature of spider venom knottnins is the hydrophobic patch surrounded by charged amino acids on the toxin’s surface [72,73] that contributes to potency and selectivity [74–83]. The UniProt database lists 747 entries on search term “spider venom ICK toxin” (23 September 2019) that are further categorized into their ion channel targets (Figure 3) which shows approximately 43% of the thus far described ion channel-impairing spider knottnins targeted Na$^+$ channel [84].
Figure 2. (A) Top: Spider venom knottin HwTx-IV (PDB: 2m50) [83] demonstrating the cystine knot motif with three disulphide bridges. A ring structure made up of two disulphide bridges, C1–C4 and C2–C5 (yellow), and the intervening peptide backbone (pink) penetrated by a third disulphide bridge, C3–C6 (orange), to form a pseudo-knot. The three-disulphide bonds form four loops (pink, green and cyan). Below: The primary structure of HwTx-IV with three disulphide bridges and four loops. (B,C) Spider venom knottins with varying β-sheet topology. The colour from the N-terminal to the C-terminal follows the rainbow spectrum from blue to red. (B) HnTx-IV (PDB: 1NIY) [85] comprises three β-sheets, whereas (C) CcoTx-I (PDB: 6BR0) [86] comprises two β-sheets.

Figure 3. Number of spider venom knottins modulating ion channels. The data were collected from the UniProt database on 23 September 2019 using the following search descriptors: “voltage gated sodium channel impairing spider ICK toxin” for NaV channel targeting spider knottins, “voltage gated calcium channel impairing spider ICK toxin” for voltage-gated calcium (CaV) channel targeting spider knottins, “voltage gated potassium channel impairing spider ICK toxin” for voltage-gated potassium (Kv) channel targeting spider knottins, “TRP impairing spider ICK toxin” for transient receptor potential (TRP) channel targeting spider knottins, “ionotropic glutamate receptor impairing spider ICK toxin” for ionotropic glutamate receptor (GluR) targeting spider knottins, “calcium-activated potassium channel impairing spider ICK toxin” for calcium-activated potassium (KCa) channel targeting spider knottins, “mechanosensitive ion channel impairing spider ICK toxin” for mechanosensitive ion channel (MSIC) targeting spider knottins and “ASIC impairing spider ICK toxin” for acid-sensing ion channel (ASIC) targeting spider knottins [84].
The first discovery of Na\textsubscript{V}-modulating spider venom peptides was in the mid-1980s, when Fontana and Vital-Brazil [87] demonstrated that the crude venom of \textit{Phoneutria nigriventer} is capable of activating Na\textsubscript{V} channels in muscle and nerve cells. Later in 1991, Rezende et al. [88] isolated three neurotoxic fractions (PhTx1, PhTx2 and PhTx3) from \textit{P. nigriventer} venom, and the most toxic fraction (PhTx2) was later shown by Araújo et al. [89] in 1992 to inhibit the Na\textsubscript{V} channel inactivation. In 1989, Adams et al. [90] isolated \(\mu\)-agatoxins (I–VI) from \textit{Agelenopsis aperta} which became the first spider venom with disulphide-rich peptides (8 cysteines arranged into 4 disulphide bridges) targeting Na\textsubscript{V} channels to induce repetitive firing in the neurons. Since then, a journey of three decades of research on spider venom peptides modulating Na\textsubscript{V} channels resulted in the discovery of a number of venom peptides which have been applied into research on the mechanisms of Na\textsubscript{V} channel modulation and potential therapeutics. Based upon the level of sequence identity and inter-cysteine spacing, these Na\textsubscript{V} channel-targeting spider toxins were classified into 12 families (NaSpTx1–12) [15].

### 3.1. Pharmacology of NaSpTx

The spider knottins’ interaction with Sites 3 and 4 displayed diverse pharmacological phenotypes (Tables 1 and 2). Broadly, they either (i) prevent channel opening in response to membrane depolarization by trapping the VSD II in the closed state; (ii) facilitate channel opening by trapping VSD II in open state or (iii) prevent channel inactivation by binding DIV S4 in the closed state to impair the movement of the inactivation gate [15, 18, 63]. Curiously, an integrated pharmacology of Site 3 and Site 4 indicates multiple binding site interactions by the same toxin [91, 92]. For example, the toxic fraction PhTx2 from the venom of \textit{P. nigriventer} not only prolonged the inactivation and deactivation (Site 3 phenotype) of the Na\textsubscript{V} channel but also shifted the voltage dependence of activation (Site 4 phenotype) and steady-state inactivation towards negative potentials (Site 3 phenotype) [89]. Later, PnTx2–6 alone confirmed this complex pharmacology was achieved by a single toxin [93]. Further evidence of dual pharmacological profile includes versutoxin (VTX) from \textit{Hadronyche versuta}, which besides the classical Site 3 features, such as delaying the channel inactivation and shifting the voltage dependence of inactivation towards more negative potential, also displayed the classical Site 4 feature of reducing the maximum (peak) sodium current [94].

#### Table 1. Pharmacological features of Site 3 interacting spider knottins resulting in delay of channel inactivation.

| Features | Examples |
|----------|----------|
| Hyperpolarizing shift in voltage-dependence of activation | PhTx-2 [89], VTX [94], Hv1 [95], Ar1 [96], Hv1b [97], PnTx2-6 [93], JzTx-II [98] |
| Hyperpolarizing shift in steady-state inactivation | VTX [94,99], PhTx-2 [89], Ar1 [89], Hv1b [97], PnTx2-6 [93] |
| No significant effect in voltage-dependence of steady-state inactivation | JzTx-I [100,101], JzTx-II [98] |
| Reduced peak inward current amplitude | VTX [94], Ar1 [96], Hv1b [97], PnTx2-6 [93] |
| No change in peak inward current amplitude | JzTx-I [100] |
| Increased peak inward current amplitude | Hm1a [20] |
| Increased recovery rate from inactivation | VTX [94], Ar1 [96], JzTx-I [102], JzTx-II [98] |
| Decreased recovery rate from inactivation | PnTx2-6 [93] |
### Table 2. Pharmacological features of Site 4 interacting spider knottins resulting in reduction of peak inward current.

| Features                                                                 | Examples                                                                                                                                                                                                 |
|--------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Depolarizing shift in voltage-dependence of activation                   | ProTx-I [103], ProTx-II [77,103,104], JzTx-III [105,106], CcoTx-I [73], CcoTx-2 [73], CcoTx-3 [73], PaurTx-3 [73], JzTx-V [79,107], JzTx-IX [108], Hm-3 [109], Cda1 [110], Pre1a [111], Pn3a [61], Df1a [92], JzTx-XI [91], JzTx-35 [112] |
| No effect in voltage-dependence of activation                            | HwTx-IV [104,113–115], HnTx-III [116,117], JzTx-34 [118,119], Hm-1 [120], Hm-2 [120], Hd1a [121], GpTx-1 [122], Hl1a [123], PrnTx1 [124], ProTx-III [80], Pre1a [111], JzTx-14 [125] |
| Hyperpolarizing shift in voltage-dependence of steady-state inactivation | HnTx-III [116], HnTx-IV [116], JzTx-V [79], Hm-1 [120], Hm-2 [120], JzTx-35 [112], PrnTx4 (5-5) [126], Df1a [92], JzTx-34 [119] |
| Delay in channel inactivation                                            | ProTx-II [104], JzTx-XI [91], Df1a [92], JzTx-14 [125]                                                                                                                                               |
| Decreased channel recovery from inactivation                            | HnTx-III [116], JzTx-XI [91], Pn3a [61]                                                                                                                                                              |
| No effect in channel recovery from inactivation                          | HnTx-IV [116], JzTx-34 [118], HnTx-III [127], Df1a [92]                                                                                                                                              |
| Hyperpolarizing shift in voltage-dependence of activation                | HnTx-IV [116], JzTx-34 [118], HnTx-III [127], Df1a [92]                                                                                                                                              |

Detailed characterization of the dual effects of the spider knottin JzTx-XI from *Chilobrachys jingzhao* on hNav1.5 revealed a concentration dependence in the modulation of Nav channels. At low concentrations (≤90 nM), JzTx-XI significantly reduced the peak currents (inhibition of channel activation; Site 4) but at higher concentrations (≥180 nM), besides reducing the peak currents, it also slowed the current decay (fast inactivation; Site 3) [91]. Further, these modulatory effects were demonstrated by Df1a from *Daeus fasciatus* over hNav subtypes 1.1–1.7, where the toxin shifted the voltage-dependence of activation and steady-state fast inactivation of the hNav subtypes to more hyperpolarizing potentials, with exception of depolarizing shifts in activation of hNav1.3 and hNav1.7 and depolarizing shifts in the inactivation of hNav1.3 [92]. Furthermore, the toxin delayed the fast inactivation along with the reduction of peak currents in hNav1.1, hNav1.3 and hNav1.5 [92]. Such subtype-varying profiles have also recently been reported for Pn3a (*Pamphobeteus nigricolor*) [61], Pre1a (*Psalmopoeus reduncus*) [111] and JzTx-14 (*C. jingzhao*) [125]. These multi-site effects of spider knottins on Nav channels need to be carefully considered when establishing their pharmacological profiles.

Another channel state modulated by spider knottins is channel inactivation [91,93,94,98,116]. For example, when tested over tetrodotoxin sensitive (TTX-S) Nav channels on rat dorsal root ganglia (DRG) neurons, HnTx-III and HnTx-IV from *Selenocosmia hainana* differed in their channel repriming kinetics. More specifically, HnTx-III delayed channel recovery from inactivation, whereas HnTx-IV had no effects [116]. Similarly, steady-state inactivation can also be differently modulated by spider knottins. For example, JzTx-35 (*C. jingzhao*), which selectively targeted hNav1.5 similarly to JzTx-III (*C. jingzhao*), differed by shifting the steady-state inactivation of the channel towards more hyperpolarized potentials [112]. The hyperpolarizing shift in the voltage dependence of steady-state inactivation stabilizes the channel in the inactivated state [128]. However, potent inhibitor toxins like HwTx-IV (*Ornithoctonus huwena*), ProTx-III (*Thrixopelma pruriens*) and HnTx-IV showed no effect on steady-state inactivation [80,114,129]. Likewise, the excitatory JzTx-I (*C. jingzhao*) delayed the channel inactivation of other Site 3-acting spider knottins including δ-ACTXs, but the peak current amplitude, I–V relationship and steady-state inactivation remained unaltered [101]. Such characteristics among the spider knottins provide novel paths to modulate Nav channels.

Spider knottins also inhibit Nav channel activation. ProTx-I and ProTx-II from *T. pruriens* showed, for the first time, the depression of Nav channel activation by shifting the voltage dependence of activation towards more depolarized potentials [103]. This is in contrast to typical scorpion β-toxins which, although reduced the peak current, shifted the voltage dependence of activation and inactivation...
to hyperpolarized potentials [130]. Its structural homology with hanatoxin isolated from *Glossostola spatulata* suggested interactions with the DII S3–S4 linker to inhibit the channel activation [103,131]. Later, residues critical for these interactions were identified in the domain II of the hNav channel [132]. Spider knottins include a growing number of depressant toxins, including JzTx-V (*C. jingzhao*), Df1a (*D. fasciatus*), Pre1a (*P. reduncus*), PnTx4(5-5) from *P. nigriventer*, CcoTx-1 (*Ceratogyrus cornutus*), PaurTx (*Phrixotrichus auratus*) and Cd1a (*Ceratogyrus darlingi*) which induce a depolarizing shift in voltage-dependence of activation at specific Nav subtypes [73,79,92,107,110,111]. However, a number of spider depressant knottins reduced the sodium currents without changing the activation or inactivation kinetics (e.g., HwTx-IV, HnTx-III, HnTx-IV) [114,116,129], by shifting activation and inactivation to hyperpolarizing potentials (e.g., Df1a) [92] or by inhibiting both activation and inactivation (e.g., JzTx-14) [125]. Spider knottins (e.g., JzTx-V) also altered the slope factor of activation and inactivation associated to shifts in their voltage dependence [79,91] suggesting cooperativity between the four S4 segments or multiple binding sites [9,91].

Spider knottins display distinct affinities and modes of action for insect and mammalian Nav channels. Magi 5 from *Macrothele gigas* interacted with Site 3 on the insect Nav channels and Site 4 on mammalian Nav channels to induce Na+ influx [133]. These observations support the concept of common binding “hot spots” proposed by Winterfield and Swartz (2000) [134], where binding sites in the voltage-gated ion channels are not independent structural sites. Recently, PnTx4(5-5) also showed a distinct affinity and mode of action on insect and mammalian Nav channels [126]. On BgNav from the cockroach *Blatella germanica*, PnTx4(5-5) strongly slowed channel inactivation (EC50 213 nM) and increased current amplitude, while it inhibited sodium currents of the mammalian Nav1.2–1.6 channels, with higher potency on Nav1.3. This unique selectivity and species-dependent mode of action provides new insight into the molecular mechanisms of spider gating modifier toxins [126].

Cell background can also influence pharmacological profiles of spider knottins [116,117,129]. For example, hyperpolarizing shifts (10–11 mV) in voltage-dependence of steady-state inactivation imparted by HnTx-III and HnTx-IV in TTX-S Na+ currents in rat DRG were not observed on heterologously expressed hNav1.7. Similarly, HnTX-III which delayed the recovery from inactivation of TTX-S Na+ channels on rat DRG did not affect the repriming kinetics of heterologously expressed hNav1.7 [116,117]. Indeed, the difference in the relative proportion of Nav subtypes in different DRG cell types (small and large diameter) [117], species and age [117,135], β-auxiliary subunit combinations [136] and difference in the membrane lipid composition [82] likely influence the biophysical and pharmacological properties of Nav subtypes. The pharmacological and biophysical properties of Nav channels are also influenced by the expression system and species differences. For example, Df1a was approximately 8.5 fold less potent at hNav1.7 expressed in *Xenopus* oocytes than at hNav1.7 expressed in HEK 293 cells [92]. Similarly, Pn3a was approximately 2 fold less potent at rNav1.7 and 5 fold less potent at mNav1.7 compared to hNav1.7 [61].

Interaction with membrane lipid is another important feature of spider knottins [14] that can influence affinity and potency [75,82,137]. The anionic charges in the polar head groups of the lipid surrounding Navs probably increase the affinity of positively charged spider knottins, while hydrophobic residues in these toxins can make favourable electrostatic and hydrophobic interactions with the hydrophobic core of the lipid bilayer [138]. Although spider knottins like ProTx-I and ProTx-II exploit electrostatic interactions to increase their potency, HwTx-IV and Hd1a (*Haplopelma doriae*) rely less on membrane binding for potent inhibition [139,140]. Interestingly, a HwTx-IV analogue engineered to increase the affinity for lipid membrane showed improved inhibitory potency at hNav1.7 [137]. On the other hand, the most potent and selective analogues of GpTx-1 (*Glossostola porteri*) and ProTx-II had reduced affinity for lipid bilayer [75]. Thus, a direct correlation between the toxin–lipid interaction and the potency or the selectivity for Navs could not be established [86] beyond facilitating the positioning of the toxin at the membrane surface proximal to exposed Nav residues [75]. Indeed, the conserved amphipathicity of the spider knottins may be an evolutionary adaptation favouring toxin promiscuity [86].
3.2. Structure–Function of NaSpTx

Structure–function studies highlight the role of knottin residues in determining the toxin potency and selectivity [14]. For example, the distribution of Ser4 and Asp5 at N-terminus instead of cationic Lys4 and Arg5 of δ-ACTX-Hv1b (*H. versuta*) shifted selectivity for mammalian Na\(_V\) channels [97]. Similarly, CcoTx-2 (D32Y-CcoTx-1) potently inhibited Na\(_V\)1.3 (IC\(_{50}\) 88 nM), while CcoTx-1 was inactive at this subtype. Surprisingly, Asp32 or Tyr32 located on the side opposite the hydrophobic patch also influenced potency, suggesting that residues beyond the hydrophobic patch can also influence toxin–channel interactions [73]. In addition, the ICK fold retained by key mutants suggested that specific amino acid interactions between the toxin and channel are prime in Na\(_V\) channel modulation and subtype selectivity [83,85].

The NaSpTx family 1–3 incorporate most of the Na\(_V\)-modulating spider knottins with promising therapeutic lead potential, including ProTx-II [103,141], ProTx-I [132], ProTx-III [80], Df1a [92], Pr3a [61], HwTx-IV [83,137,142,143], GpTx-I [76] and CcoTx-I [144]. Sequence alignments of selected Na\(_V\)-modulating spider knottins targeting Sites 3 and 4 in Na\(_V\) channels are shown in Figure 4. Besides the shorter N-terminus and longer C-terminus in Site 3 and Site 4 targeting spider knottins, this alignment highlights conserved hydrophobic residues in loop 1 and positively charged residues in loop 4 of Site 4 targeting spider knottins. In contrast, negatively charged residues are distributed in loop 2 of NaSpTx1–3 spider knottins and in the N-terminal of NaSpTx families 1 and 2. The conserved Arg and Lys in loop 4 of NaSpTx1–3 appear to be crucial for inhibitory function of depressant spider toxins belonging to these families [145].

![Figure 4](image-url)

**Figure 4.** Multiple sequence alignment of spider knottins targeting Site 4 and Site 3 in Na\(_V\) channels. The NaSpTx family 1–3 generally target Site 4 to inhibit channel activity, except Hm1a which targets Site 3 to excite the channel [20]. JzTx-I [125] from NaSpTx7 targets Site 4 and inhibits the channel, whereas JzTx-I [100] and JzTx-II [98] from NaSpTx7 targets Site 3 to excite the channel. Yellow highlights conserved cysteines, green highlights hydrophobic residues, cyan indicates positively charged residues, red indicates negatively charged residues and bold letter indicates the aromatic residues. The “*” indicates identical residues, “:” indicates strong conservation, “.” indicates weak conservation.

The C-terminal WCK motif is also conserved across well-characterized sodium channel-blocking toxins from NaSpTx families 1 and 3, suggesting that these residues are key determinants of activity [83]. In the cryogenic electron microscopy (cryo-EM) structure of ProTx-II–hNav1.7 VSDII-Na\(_V\)Ab complex, the corresponding Trp24 served as a hydrophobic anchor to stabilize ProTx-II interactions with hNav1.7 [58]. More specifically, the hydrophobic patch Trp5, Trp7, Trp24 and Trp30 stabilized binding...
by allowing deeper penetration into the membrane lipid [58]. In addition, the ProTx-II–hNav1.7 cryo-EM structure confirmed a key role of the C-terminal basic residues capped by hydrophobic residues in anchoring the toxin into the membrane [58]. In contrast, JzTx-14 belonging to NaSpTx7 has a loop 4 that lacks positively charged residues and Arg serving as a C-terminal cap, but still inhibits eight out of nine NaV channel subtypes at nanomolar concentrations [125]. It has additional hydrophobic residues in each of the four loops with only one acidic residue that suggest an alternative binding mode. Indeed, structure–function studies have shown that hydrophobic and aromatic residues in loop 1, loop 4 and C-terminus and positively charged residues distributed in loop 4 and C-terminus were critical for toxins’ affinity [83,85,117]. Interestingly, the highly Nav1.7-selective Pn3a, like other NaSpTx2 spider knottins, lacks positively charged residues in the C-terminus and instead contains hydrophobic and negatively charged Asp residues.

The overall net charge of the peptide also affects the toxin activity. For example, decreased net anionic charge in E1G, E4G, Y33W-HwTx-IV enhanced inhibition by 45 fold (IC50 0.4 nM) compared to native HwTx-IV (IC50 17 nM) [142], which was mostly driven by enhanced hydrophobic interactions associated to the Y33W mutation (IC50 1.4 nM). Amidation of the C-terminus also has a direct influence on the potency of HwTx-IV [142]. While characterizing ProTx-III and Df1a interactions with NaV channels, Cardoso et al. [80,92] elucidated the significance of C-terminal amidation in enhancing potency and altering subtype selectivity of spider toxins.

The comparison of the potency of spider knottins over Nav1.1–Nav1.8 for Site 4 (Figure 5A) and Site 3 (Figure 5B) toxins highlights the limited pharmacological data for Site 3 spider knottins that are available mostly for Nav1.3 and Nav1.5. In contrast, Site 4 targeting spider knottins preferentially target hNav1.7 with Cd1a and CcoTx-2 having clear preference over hNav1.2, making this class an excellent starting point for the design of analgesic spider knottins. Indeed, the hNav1.7 selective spider knottin Pn3a confirms this potential [61,146] and shows analgesic effects in acute postsurgical pain [146]. A more complete list of spider knottins showing potency across different NaV channel subtypes and DRG are listed in Appendix A Tables A1 and A2.
Figure 5. “Spider-plot” of Site 4 and Site 3 targeting spider knottins. (A) The pIC\textsubscript{50} of Site 4 spider knottins normalized against Na\textsubscript{V}1.7 are shown. These data are from assays performed on human Na\textsubscript{V} subtypes, except JzTx-14 which was performed at mammalian Na\textsubscript{V} subtypes. Data for GpTx-1 [122], ProTx-III [80], Cd1a [110], and CcoTx-2 [110] were obtained from Fluorescence Imaging Plate Reader (FLIPR) experiments, while the remainder were acquired using electrophysiology. Black dots indicate that the IC\textsubscript{50} values for the corresponding knottins were less potent than the value indicated. (B) The pEC\textsubscript{50} of Site 3 targeting spider knottins are shown. JzTx-I [100] was tested on rat Na\textsubscript{V}1.2–1.4 and human Na\textsubscript{V}1.5 and Na\textsubscript{V}1.7. JzTx-II [98] was tested on rat Na\textsubscript{V}1.3 and human Na\textsubscript{V}1.5. PnTx2-1 [147] was tested on rat Na\textsubscript{V}1.1 and Na\textsubscript{V}1.8, and human Na\textsubscript{V}1.5. Hm1a [20] was tested on human Na\textsubscript{V} subtypes.

Mutagenesis and chimera studies of Na\textsubscript{V} channels are typically used to determine critical residues for toxin binding on hNa\textsubscript{V} channels [92,129,148]. These studies have revealed why the spider knottins HnTx-III, HnTx-IV, and HwTx-IV show Site 1-like channel inhibition (pore blocker) although they are gating modifiers [113,116,128]. Specifically, the Y326S mutation in Na\textsubscript{V}1.7 decreased the channel sensitivity to tetrodotoxin (TTX) but not to HwTx-IV [114], while three residues (i.e., Glu753, Asp816 and especially Glu818) outside the pore were shown to be involved in the interactions of HnTx-IV with hNa\textsubscript{V}1.7 (Figure 6A,B) [129]. hNa\textsubscript{V}1.7/rK\textsubscript{V}2.1 S3–S4 paddle chimera studies revealed that Df1a primarily interacted with the DII voltage sensor of hNa\textsubscript{V}1.7 and had weaker interactions with VSDs of DIII and DIV [92]. Wingerd et al. [111] showed that the spider knottin Pre1a interacted with the DII and DIV S3–S4 loops of Na\textsubscript{V}1.7 as well as the S1–S2 loop of DIV with the latter interaction likely conferring subtype selectivity. They also showed the role of the serine residue in the DIV S2 helix of hNa\textsubscript{V}1.1.
(Figure 6C) and rNav1.3 in inhibiting the fast inactivation process in these channel subtypes [111]. Spider knottin Hm1a also targets DIV S3b–S4 and S1–S2 loops that likely underlie its subtype selectivity for hNav1.1 [20].

![Figure 6C](image)

| DIV S1 | DIV S1–S2 | DIV S2 |
|--------|-----------|--------|
| hNav1.1 | C I V L N T L F M A M E H Y P M T D H F N V L T V G N L V F T | hNav1.6 |
| hNav1.2 | C I V L N T L F M A M E H Y P M T E Q F S S V L S V G N L V F T | hNav1.7 |
| hNav1.3 | C I V L N T L F M A M E H Y P M T E Q F S S V L S V G N L V F T | hNav1.8 |
| hNav1.4 | C I V L N T L F M A M E H Y P M T E H F D N V L T V G N L V F T | hNav1.9 |
| hNav1.5 | C I V L N T L F M A M E H Y N M T S E F E E M G Q V G N L V F T | hNav1.10 |
| hNav1.6 | C I V L N T L F M A M E H Y P M T P Q F E H V L A V G N L V F T | hNav1.11 |
| hNav1.7 | C I V L N T L F M A M E H Y P M T E F K N V L A I G N L V F T | hNav1.12 |
| hNav1.8 | C I V L N T L F M A M E H Y P M T E F K N V L A I G N L V F T | hNav1.13 |
| hNav1.9 | C I V L N T L F M A M E H Y P M T E F K N V L A I G N L V F T | hNav1.14 |

| DII S3 | DII S3–S4 | DII S4 |
|--------|-----------|--------|
| hNav1.1 | L S M V L G - - L A R Y E G L S V L R S F R L L | hNav1.5 |
| hNav1.2 | L S M V L G - - L A R Y E G L S V L R S F R L L | hNav1.6 |
| hNav1.3 | L S M V L G - - L A R Y E G L S V L R S F R L L | hNav1.7 |
| hNav1.4 | L S M V L G - - L A R Y E G L S V L R S F R L L | hNav1.8 |
| hNav1.5 | L S M V L G - - L A R Y E G L S V L R S F R L L | hNav1.9 |
| hNav1.6 | L S M V L G - - L A R Y E G L S V L R S F R L L | hNav1.10 |
| hNav1.7 | L S M V L G - - L A R Y E G L S V L R S F R L L | hNav1.11 |
| hNav1.8 | L S M V L G - - L A R Y E G L S V L R S F R L L | hNav1.12 |
| hNav1.9 | L S M V L G - - L A R Y E G L S V L R S F R L L | hNav1.13 |

**Figure 6.** Sequence alignment of (A) DII S1–S2, (B) DII S3–S4, (C) DII S1–S2 and (D) DII S3–S4 of hNav1.1–1.9. Identical residues among hNav subtypes are highlighted in red. hNav1.9 demonstrates the highest variation compared to other hNav subtypes. Boxes highlights key residues in the interactions for the spider knottins HwTx-IV [149], HnTx-IV [129], ProTx-II [58,104], JzTx-III [106], JzTx-II [98], JzTx-I [100], JzTx-34 [119] and Pre1a [111].

Certain spider knottins can interact with multiple sites in the channel as demonstrated by ProTx-II’s interactions at DII and DIV of hNav1.7 (Figure 6B,D) [55,104]. Furthermore, the DII residues, Glu753, Glu811, Leu814, Asp816 and Glu818, in hNav1.7 that are critical for inhibition of activation by HwTx-IV are partially conserved in hNav1.7 DIV. However, the partial conservation of DII residues in DIV (EgLDI) in wild-type hNav1.7 made HwTx-IV interact specifically with DII [149].
Mutational studies further identified that Asp1609 in hNa\textsubscript{V}1.5 was crucial in determining the JzTx-II potency. However, rNa\textsubscript{V}1.8 and rNa\textsubscript{V}1.9 resistant to JzTx-II have Ala and Arg, respectively, instead of Asp1609 [98]. Similarly, Glu818 in hNa\textsubscript{V}1.7 is conserved in HnTx-IV-sensitive Na\textsubscript{V} channels rNa\textsubscript{V}1.2 and rNa\textsubscript{V}1.3 but is replaced by a neutral amino acid in HnTx-IV-resistant rNa\textsubscript{V}1.4 and hNa\textsubscript{V}1.5 [129]. In addition, Schmalhofer et al. [132] showed the crucial role of Phe813 in ProTx-II’s selectivity for hNa\textsubscript{V}1.7 over other Na\textsubscript{V} subtypes. Finally, cysteine palmitoylation, which is a common reversible lipid modification process vital for Na\textsubscript{V} channel biosynthesis, is also associated with the affinity of spider knottins to Na\textsubscript{V} channels [150]. It regulates the gating and pharmacology of WT-rNa\textsubscript{V}1.2a as observed by the hyperpolarizing shift in steady-state inactivation and slowing in the channel recovery from fast inactivation upon depalmitoylation of intracellular cysteines on both WT-rNa\textsubscript{V}1.2a and G1097C-rNa\textsubscript{V}1.2a [150].

4. Knottins for Na\textsubscript{V}s in Pain Pathways

Pain allows direct perception of noxious stimuli to avoid actual or potential tissue damage. Primary sensory neuron (nociceptor) signals are transmitted to the brain through action potentials generated by ion channels and receptors. Genetic and molecular studies in animals and humans identified six Na\textsubscript{V} channel subtypes (i.e., Na\textsubscript{V}1.1, Na\textsubscript{V}1.3, Na\textsubscript{V}1.6, Na\textsubscript{V}1.7, Na\textsubscript{V}1.8 and Na\textsubscript{V}1.9) critical for the generation and transmission of pain-related signals [20,21,36,151–158]. The Na\textsubscript{V}1.7, Na\textsubscript{V}1.8 and Na\textsubscript{V}1.9 are preferentially expressed in the peripheral nervous system (PNS), while Na\textsubscript{V}1.1 and Na\textsubscript{V}1.6 are found in both the central nervous system (CNS) and PNS. The subtype Na\textsubscript{V}1.3 is generally expressed in the CNS and absent in the adult PNS but is re-expressed in peripheral pain-signalling pathways upon neuronal injury [21,154,159]. The CNS localization of Na\textsubscript{V}1.3, Na\textsubscript{V}1.7, Na\textsubscript{V}1.8 and Na\textsubscript{V}1.9 avoids reaching the CNS and inducing associated off-target side effects. Besides these four major peripheral targets, there is evidence of the involvement of Na\textsubscript{V}1.6 [160–162] and Na\textsubscript{V}1.1 [20] in various peripheral pain pathways, which suggests these might also be drug targets in chronic pain types.

4.1. Na\textsubscript{V}1.1

Voltage-gated sodium channel subtype 1.1 (Na\textsubscript{V}1.1) is a TTX-S sodium channel encoded by the SCN1A gene located on human chromosome 2q24.3 [163]. They initiate action potential and repetitive firing in neurons and are expressed in both the CNS and PNS and including the colonic myenteric plexus [17,164]. In the PNS, Na\textsubscript{V}1.1 is predominantly expressed in medium-to-large diameter DRG neurons (A-fibres) but less expressed in small diameter unmyelinated neurons (i.e., C-fibres [165,166]) and has a smaller contribution in C-fibre-mediated nociceptive transmission [166,167]. However, in colonic afferents which predominantly comprise C-fibres, nearly 50% of the neurons are expressed Na\textsubscript{V}1.1 [168]. The hNa\textsubscript{V}1.1-selective activator Hm1a revealed its role in mechanical but not thermal hypersensitivity in the absence of neurogenic inflammation [20]. Recently, Salvatierra et al. [19] demonstrated the upregulation of Na\textsubscript{V}1.1 in chronic visceral hypersensitivity (CVH) and its inhibition reducing the mechanical pain in an irritable bowel syndrome (IBS) rodent model. Furthermore, Na\textsubscript{V}1.1 contributed to peripheral nerve injury-associated mechanical hypersensitivity [19].

Besides the role in nociception [19,20], Na\textsubscript{V}1.1 participates in the familial hemiplegic migraine type 3 [169]. In addition, the anti-epileptic drug rufinamide, a Na\textsubscript{V}1.1 inhibitor [170,171], alleviated spared nerve injury-evoked mechanical allodynia which also stabilizes Na\textsubscript{V}1.7 in the inactivated state [172]. In addition to the hNa\textsubscript{V}1.1-selective activator Hm1a, which identified a key role for this subtype in mechanosensitive pain, the spider knottins CcoTx-1, CcoTx-2, Df1a, ProTx-III, HwTx-IV and Pre1a inhibit Na\textsubscript{V}1.1 in the nanomolar range and are thus potential leads to novel analgesics (Table A1).

4.2. Na\textsubscript{V}1.3

Voltage-gated sodium channel subtype 1.3 (Na\textsubscript{V}1.3) is a TTX-S sodium channel encoded by the SCN3A gene located on human chromosome 2q24.3 [163]. It produces fast activating and inactivating
sodium currents and ramp currents due to the fact of its slow closed-state inactivation. These contribute to neuronal hyperexcitability by reducing thresholds and enhancing the repetitive and ectopic firing in injured neurons [17,154,173]. This channel is primarily expressed in embryonic DRG neurons and absent in adult DRG, but re-expressed during peripheral nerve injury and painful neuromas [166,174,175]. It is also expressed in enterochromaffin cells in the large and small intestine of humans and mice, where they participate in responses to chemical and mechanical stimuli [164,176,177].

Neuropathic pain models such as sciatic nerve transection [178], spinal nerve ligation (SNL) [179], SNI [180] and chronic constriction injury (CCI) confirmed the upregulation of NaV1.3 [181]. Interestingly, this channel is upregulated only when peripheral projections are transected. The upregulation of NaV1.3 is also associated to hyperexcitability of small DRG neurons [178]. Furthermore, infraorbital nerve-chronic constriction injury (ION-CCI) produced significant upregulation of NaV1.3 and downregulation of NaV1.7, NaV1.8 and NaV1.9 in trigeminal nerves [182].

Intrathecal administration of NaV1.3-targeting antisense oligonucleotides attenuated NaV1.3 upregulation and consequently reduced hyper-responsiveness of dorsal horn neurons and mitigated pain behaviours following CCI [181]. Chen et al. [156] also observed increased expression of NaV1.3 in a CCI rat model in which neuropathic pain was alleviated by the intrathecal administration of MiR-96, a microRNA that inhibits NaV1.3 expression. Another microRNA miR-30b attenuated SNL-evoked neuropathic pain by targeting SCN3A and downregulating the expression of NaV1.3 mRNA and protein both in DRG neurons and the spinal cord [157].

The role of NaV1.3 is also demonstrated in inflammatory pain [183], where its expression was upregulated in DRG neurons of rats with diabetic neuropathy and showing mechanical allodynia and thermal hyperalgesia [184]. In this same model, NaV1.3 knockdown by adeno-associated virus (AAV)-shRNA-NaV1.3 vector reduced neuropathic pain [185]. Varicella zoster virus (VZV) infection causing post-herpetic neuralgia (PHN) also showed upregulation of NaV1.3 [186]. However, although NaV1.3 was downregulated by antisense oligonucleotides in an SNI model, mechanical and cold allodynia were not attenuated [180]. Similarly, the mechanical allodynia remained unaltered following nerve injury in nociceptor specific and global NaV1.3 knockout mouse models [187]. The druggability of NaV1.3 in chronic pain management requires NaV1.3-selective inhibitors [17]. Spider knottins ProTx-II, ProTx-III, HwTx-IV, HnTx-III, HnTx-IV and CcoTx-2 have nanomolar potency towards NaV1.3 and rational engineering may generate NaV1.3-selective leads (Table A1).

4.3. NaV1.6

Voltage-gated sodium channel subtype 1.6 (NaV1.6) is a TTX-S sodium channel encoded by the SCN8A gene which is located in human chromosome 12q13.13 [163]. They localize at the axon initial segment (AIS) and nodes of Ranvier in the CNS and PNS, including central projections and soma of the C-fibres [188–190]. It underlies persistent and resurgent sodium currents and repetitive neuronal excitability, with loss- or gain-of-function mutations reducing or increases the neuronal excitability, respectively [188]. Persson et al. [191] demonstrated the expression of NaV1.6 in the axons of small nerve bundles beneath the epidermis and in the nerve terminals of nociceptors. Its increased expression is observed in complex regional pain syndrome Type 1 (CRPS1), post-herpetic neuralgia (PHN) patients [162,192] and in diabetic neuropathy in mice [193]. Recently, gain-of-function mutation M136V in NaV1.6 was reported in trigeminal neuralgia with significantly increased peaks inward, resurgent currents and overall excitability of trigeminal nerves [194,195]. Deuis et al. [160] showed that oxaliplatin-induced cold allodynia is mediated by NaV1.6 expressed in peripheral pathways, suggesting a key role in cold pain pathways. Finally, the selective inhibitor Cn2-E15R developed from the NaV1.6 agonist Cn2 can be used to determine the extent of NaV1.6 contributions to pain behaviours [196].

Local knockdown of NaV1.6 alleviated spontaneous pain and mechanical allodynia imparted by the scorpion toxin BmK I [161]. Furthermore, local NaV1.6 knockdown reversed mechanical pain in an SNL rat model by reducing sympathetic sprouting around NaV1.6-positive neurons [197].
The Na\textsubscript{V}1.6 expression was also upregulated in a pain model of DRG inflammation where Na\textsubscript{V}1.6 knockdown reduced the pain behaviours and the abnormal bursting of the sensory neurons, including nociceptors [198]. Spider knottins modulating Na\textsubscript{V}1.6 at nanomolar concentrations include ProTx-II, HwTx-IV, JZTx-14, Pre1a and Df1a (Table A1).

4.4. Na\textsubscript{V}1.7

Voltage-gated sodium channel subtype 1.7 (Na\textsubscript{V}1.7) is encoded by the SCN9A gene which is located in human chromosome 2q24.3 [163]. It is preferentially expressed in large-and-small diameter DRG neurons, visceral sensory neurons, olfactory sensory neurons, trigeminal ganglia and sympathetic neurons [151,152,199]. In DRG neurons, they are present from the peripheral to central terminals, with higher expression in small-diameter DRG neurons (C-fibres) [200]. This channel produces a rapidly activating and inactivating TTX-S sodium current that slowly recovers from inactivation and limits the frequency of firing. The slower onset of closed-state inactivation also limits inactivation during sub-threshold depolarizations and facilitates robust action potential generation that can amplify sub-threshold inputs [152,153,201,202]. Besides action potential generation and propagation, Na\textsubscript{V}1.7 also contributes to neurotransmitter release in peripheral and central projections of sensory neurons [151,153].

Exclusive localization in the PNS and compelling genetic and functional evidences have centre-staged Na\textsubscript{V}1.7 in pain research [153,158,203,204]. For example, mutations have been identified for various gain-of-function pain disorders, such as inherited erythromelalgia (IEM) [204], paroxysmal extreme pain disorder (PEPD) [203], small fibre neuropathy (SFN) [158] and painful diabetic peripheral neuropathy [205]. The gain-of-function mutations lead to hyperpolarizing shifts in activation, increased amplitude of ramp current, impaired inactivation, increased persistent currents and enhanced resurgent currents, all contributing to the hyperexcitability of DRG neurons [152]. Similarly, recessively inherited loss-of-function mutations are linked to congenital insensitivity to pain (CIP), with loss of olfaction being the only known side effect [36]. In addition, Na\textsubscript{V}1.7 was upregulated in rodent models of visceral hypersensitivity [164]. These observations have supported Na\textsubscript{V}1.7 as a promising therapeutic target for pain [153]. Considering the recent opportunities for spider knottins to unravel the mechanisms of Na\textsubscript{V} modulation, the discovery and engineering of spider knottins selectively inhibiting Na\textsubscript{V}1.7 provided exciting new opportunities for the development of novel pain therapeutics [135]. A number of spider knottins (Table A1) show nanomolar potency to inhibit Na\textsubscript{V}1.7, with several undergoing optimization through saturation mutagenesis, directed evolution and/or rational engineering to enhance the potency and selectivity [14].

4.5. Na\textsubscript{V}1.8

Voltage-gated sodium channel subtype 1.8 (Na\textsubscript{V}1.8) is a TTX-R sodium channel encoded by the SCN10A gene in human chromosome 3p22.2 [163] and preferentially expressed in nociceptive DRG and trigeminal neurons (>90%) as well as in low-threshold mechanoreceptors [206,207], skin free nerve terminals [162], and corneal neurons [208]. It generates slowly inactivating rapidly repriming TTX-R sodium currents with a depolarized shift in the voltage dependence of activation and inactivation [154,209,210]. The channel also contributes to slow resurgent currents that probably underlie the excitability of nociceptors in DRG [211]. It also contributes significantly to the action potential upstroke and are sometimes referred to as overshoot channels [212].

The role of Na\textsubscript{V}1.8 in inflammatory pain has been well documented. It had increased expression in DRG neurons when carrageenan was injected into rat hind paw [213] and in cultured DRG neurons treated with inflammatory mediators [214,215]. Similarly, Beyak et al. [216] showed increased Na\textsubscript{V}1.8 currents in an animal model of colitis. Notably, inhibition of inflammatory pain induced by complete Freund’s adjuvant (CFA) was observed in antisense-mediated Na\textsubscript{V}1.8 knockdown in rats [217]. In addition, the upregulation of Na\textsubscript{V}1.8 in a mouse model of bowel obstruction underpins its role in visceral hypersensitivity [218]. However, its role in neuropathic pain is not well defined with studies
demonstrating downregulation of Na\textsubscript{V}1.8 mRNA, protein and currents in the sciatic nerve after axonal transection [219–221]. On the other hand, increased Na\textsubscript{V}1.8 levels were reported in spared axons and neuronal cell bodies of uninjured nerves [222,223]. This discrepancy is probably associated to the effects of inflammatory mediators in neuropathic pain models [154]. Finally, gain-of-function mutations of Na\textsubscript{V}1.8 identified in painful neuropathy cases suggest its role in peripheral neuropathy [224]. Although a few spider toxins such as ProTx-I, ProTx-II and JxTx-14 targeted Na\textsubscript{V}1.8 at nanomolar concentrations, only the spider knottin HIIa shows selectivity towards Na\textsubscript{V}1.8 (Table A1).

4.6. Na\textsubscript{V}1.9

Voltage-gated sodium channel subtype 1.9 (Na\textsubscript{V}1.9) is encoded by the SCN11A gene located in the human chromosome 3p22.2 [163]. These TTX-R channels are preferentially expressed in nociceptive DRG neurons, trigeminal ganglia and myenteric neurons [225,226], where they are activated only at hyperpolarized potentials near resting membrane potential to produce ultra-slow inactivating and persistent sodium currents [227]. These biophysical properties assist in amplifying subthreshold stimuli, lowering the threshold for single action potentials, and increasing repetitive firing [151,227,228].

The role of Na\textsubscript{V}1.9 has been demonstrated in inflammatory pain with increased Na\textsubscript{V}1.9 current density and lower thresholds for action potential generation that ultimately enhances neuronal excitability [151,214,229]. Indeed, Na\textsubscript{V}1.9 knockout mice showed diminished mechanical hypersensitivity to formalin and CFA and failed to develop thermal hyperalgesia upon CFA or carrageenan injection [151,230–232]. Rare dominant gain-of-function mutations in SCN11A have been reported in a number of human pain disorders, such as familial episodic pain [233], painful small fibre neuropathy [234,235] and insensitivity to pain [155]. Despite the challenges in obtaining heterologous expression of Na\textsubscript{V}1.9, chimeras Na\textsubscript{V}1.9/K\textsubscript{V}2.1 showed ProTx-I interacted with Na\textsubscript{V}1.9 S3b–S4 paddle motif and potentiated Na\textsubscript{V}1.9 currents in rat DRG [236].

5. Conclusions and Future Directions

In addition to a pivotal role of Na\textsubscript{V}1.7 in pain processing, other Na\textsubscript{V} subtypes including Na\textsubscript{V}1.1, 1.3, 1.6, 1.8, and 1.9 are increasingly showing supportive and/or pivotal roles in various acute and chronic pain conditions. A large range of spider knottins modulate the Na\textsubscript{V} function and continue to be developed as potential analgesic leads. In addition, spider knottins provide exquisite research tools to further explore the role of Na\textsubscript{V} channels and how they can be modulated. Given that multiple sodium channels often contribute to chronic pain conditions, therapeutic leads targeting multiple Na\textsubscript{V} channels could be advantageous; for example, chronic visceral pain may be best treated by a Na\textsubscript{V}1.1/Na\textsubscript{V}1.7/Na\textsubscript{V}1.8 inhibitor, while diabetic neuropathy may be best treated by a Na\textsubscript{V}1.3/Na\textsubscript{V}1.6/Na\textsubscript{V}1.7 inhibitor. However, despite Na\textsubscript{V}-inhibiting spider knottin potential to target multiple subtypes, most have been optimized for potency and selectivity towards a single channel subtype hNa\textsubscript{V}1.7 [14]. This review summarises spider knottin Na\textsubscript{V} channel pharmacology that might be useful in guiding structure–function studies and the rational design of multi-valent spider knottin leads towards the development of therapeutic leads for chronic pain management.

Author Contributions: Conceptualization, F.C.C. and R.J.L.; data curation, Y.D.; writing—original draft preparation, Y.D.; writing—review and editing, F.C.C. and R.J.L.; supervision, F.C.C. and R.J.L.; project administration, R.J.L.; funding, R.J.L.

Funding: This research was funded by an Australian NHMRC Program Grant (APP1072113) and a Principal Research Fellowship to R.J.L.

Conflicts of Interest: The authors declare no conflict of interest.
### Appendix A

**Table A1.** Inhibitory effects of spider knottins on Na\textsubscript{V} channel subtypes. Values presented were obtained from electrophysiological experiments unless otherwise as stated.

| Toxin      | NaSpTx Family | Nav1.1 | Nav1.2 | Nav1.3 | Nav1.4 | Nav1.5 | Nav1.6 | Nav1.7 | Nav1.8 | Nav1.9 | Others |
|------------|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ProTx-I    | 2             |        |        |        |        |        |        |        |        |        | 51 nM  |
|            |               |        |        |        |        |        |        |        |        |        | (n, X, h) |
|            |               |        |        |        |        |        |        |        |        |        | 72 nM (s, X, h) [103] |
| ProTx-II   | 3             |        |        |        |        |        |        |        |        |        | 27 nM  |
|            |               |        |        |        |        |        |        |        |        |        | (n, X, r) |
| ProTx-III  | 1             |        |        |        |        |        |        |        |        |        | 52.9 nM |
|            |               |        |        |        |        |        |        |        |        |        | (n, H, r) |
|            |               |        |        |        |        |        |        |        |        |        | [104] |
| GP-W7Q-W30L| 3             |        |        |        |        |        |        |        |        |        | 6310 nM |
| ProTx-II   |               |        |        |        |        |        |        |        |        |        | (s, C, h) |
| ProTx-III  | 1             |        |        |        |        |        |        |        |        |        | 60 nM  |
|            |               |        |        |        |        |        |        |        |        |        | rec-G; 101 nM, s-OH; 11.3 nM, s-NH\textsubscript{2} (H, h) [80] |
|            |               |        |        |        |        |        |        |        |        |        | 21.9 nM |
|            |               |        |        |        |        |        |        |        |        |        | rec-G; 41.3 nM, s-OH; 11.5 nM, s-NH\textsubscript{2} (H, h) [80] |
|            |               |        |        |        |        |        |        |        |        |        | >500 nM |
|            |               |        |        |        |        |        |        |        |        | rec-G and s-OH; >50 nM, s-NH\textsubscript{2} (H, h) [80] |
|            |               |        |        |        |        |        |        |        |        |        | 9.5 nM  |
|            |               |        |        |        |        |        |        |        |        |        | rec-G; 11.5 nM, s-OH; 2.5 nM, s-NH\textsubscript{2} (H, h) [80] |
Table A1. Cont.

| Toxin  | NaSpTx Family | Nav1.1 | Nav1.2 | Nav1.3 | Nav1.4 | Nav1.5 | Nav1.6 | Nav1.7 | Nav1.8 | Nav1.9 | Others                  |
|--------|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------------------------|
| HwTX-IV| 1             | 41 nM (n, H, r) [237] | 150 nM (n, H, r) [114] | 10 nM, s-NH2, 54 nM, rec (H, h) [83] | 44 nM (n, H, h) [237] | 338 nM (n, H, r) [114] | 400 nM (n, H, r) [114] | >10,000 nM (n, H, h) [114] | 52 nM (n, H, h) [237] | 17 nM (s, H, h) [142] | >10,000 nM (n, H, h) [237] | 30 nM (n, TTX-S currents, rat DRG) [113] |

22.7 nM (n, H, h) [104]
26 nM (n, H, r) [114]
16 nM, s-NH2, 55 nM, rec (H, h) [83]
100 nM (n, H, h) [237]
32.6 nM (n, H, h, Manual ephys) [237]
Table A1. Cont.

| Toxin               | NaSpTx Family | Nav1.1          | Nav1.2          | Nav1.3          | Nav1.4          | Nav1.5          | Nav1.6          | Nav1.7          | Nav1.8          | Nav1.9          | Others                                      |
|---------------------|---------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|---------------------------------------------|
| E1G-E4G-Y33W        |               | 8.4 nM (rec, H, h) [143] | 11.9 nM (rec, H, h) [143] | 7.2 nM (rec, H, h) [143] | 369 nM (rec, H, h) [143] | Insensitive up to 1000 nM (rec, H, h) [143] | 6.8 nM (rec, C, h) [143] | 0.4 nM (s, H, h) [142] | Insensitive up to 1000 nM (rec, C, h) [143] | 3.3 nM (rec, C, h) [143] |
| HwTx-IV             | 1             | 1100 nM (rec, H, h, FLIPR) [143] | 540 nM (rec, H, h, FLIPR) [143] | 1400 nM (rec, H, h, FLIPR) [143] | >30,000 nM (rec, H, h, FLIPR) [143] | >30,000 nM (rec, H, h, FLIPR) [143] | 5100 nM (rec, H, h, FLIPR) [143] | >30,000 nM (rec, H, h, FLIPR) [143] |
| E1G-E4G-F6W-Y33W    |               | 7.55 nM (s, S, h, FLIPR) [137] |
| HwTx-IV             | 1             | 68,000 nM (n, X, r) [145] | >10,000 nM (s, H, h) [238] | No inhibition of TTX-S and TTX-R currents up to 100,000 nM [145] |
| G7W-N24S            |               | 440 nM (rec, C, h) [81] |
| HnTx-I              | 1             | 491 nM (n, H, h) [117] | No activity [117] | No activity [117] | No activity [117] | No activity [117] | No activity [117] | No activity [117] | No activity [117] | No activity [117] | No activity [117] |
| HnTx-III            | 1             | 1270 nM (n, H, h) [117] | 275 nM (n, H, h) [117] | 491 nM (n, H, h) [117] | No activity [117] | No activity [117] | No activity [117] | No activity [117] | No activity [117] | No activity [117] | 1.1 nM (TTX-S rat DRG); No inhibition in TTX-R currents [116] |
| Toxin     | NaSpTx Family | Nav1.1                  | Nav1.2                  | Nav1.3                  | Nav1.4                  | Nav1.5                  | Nav1.6                  | Nav1.7                  | Nav1.8                  | Nav1.9                  | Others                                      |
|-----------|---------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|--------------------------------------------|
| HnTx-IV   | 1             | 36.1 nM (n, H, r) [129] | 375 nM (n, H, r) [129] | >10,000 nM (n, H, r) [129] | No inhibition up to 1000 nM [129] | 21 nM (s, n, H, h) [127] |                                      | 44.6 nM (TTX-S rat DRG) [116] |                                      |
| JzTx-III  | 7             | No effect [106]         | No effect [106]         | No effect [106]         | 348 nM (rec, H, h) [106] | No effect [106]         | No effect [106]         | No effect [106]         | 380 nM (n, rat cardiac myocytes) [105] |
| JzTx-V    | 3             | 292 nM (s, H, h) [79]   | 5.12 nM (s, H, r) [79]  | 2700 nM (s, H, h) [79]  | 61 nM (s, H, h) [79]    |                                      | 27.6 nM (n, TTX-R currents, rat DRG); 30.2 nM (n, TTX-S currents, rat DRG) [107] |
| JzTx-IX   | 2             | 5420 nM (n, H_T) [108]  | 450 nM (n, H_T) [108]   |                                      |                                      | 650 nM (n, TTX-R currents, rat DRG); 360 nM (n, TTX-S currents, rat DRG) [108] |                                      |
| JzTx-XI   | 2             | 124 nM (n, C) [91]      |                                      |                                      |                                      |                                      |                                      |                                      |                                      |
**Table A1.** Cont.

| Toxin   | NaSpTx Family | Nav1.1 | Nav1.2 | Nav1.3 | Nav1.4 | Nav1.5 | Nav1.6 | Nav1.7 | Nav1.8 | Nav1.9 | Others                                                                 |
|---------|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|------------------------------------------------------------------------|
| JzTx-14 | 3             | 194 nM | 426.3 nM | 290.1 nM | 478 nM | 158.6 nM | 188.9 nM | 824 nM |        |        | 85 nM (rec, TTX-S currents, rat DRG); No inhibition in TTX-R currents [118] |
|         |               |        |        |        |        |        |        |        |        |        | 91 nM (s, TTX-S currents, rat DRG); No inhibition in TTX-R currents [119] |
| JzTx-34 | 2             | 3 nM   | 7950 nM | 478 nM | 158.6 nM | 188.9 nM | 824 nM |        |        |        | 610 nM (s, H<sub>T</sub>, h) [119] No inhibition (s, ND cells, h) [119] |
|         |               |        |        |        |        |        |        |        |        |        | No inhibition in TTX-R currents [119] |
| JzTx-35 | 2             | 323 nM | 888 nM | 3 nM   | 478 nM | >10,000 nM | >10,000 nM | >10,000 nM | >10,000 nM | >10,000 nM | 55% block (n, H, h, FLIPR) [110] |
| CcoTx-1 | 1             | 523 nM | 3 nM   | 888 nM | 323 nM | 5120 nM | >10,000 nM | >10,000 nM | >10,000 nM | >10,000 nM | 55% block (n, H, h, FLIPR) [110] |
|         |               |        |        |        |        |        |        |        |        |        | 85 nM (rec, TTX-S currents, rat DRG); No inhibition in TTX-R currents [118] |
|         |               |        |        |        |        |        |        |        |        |        | 91 nM (s, TTX-S currents, rat DRG); No inhibition in TTX-R currents [119] |

**JzTx-14**

| Toxin | Nav1.1 | Nav1.2 | Nav1.3 | Nav1.4 | Nav1.5 | Nav1.6 | Nav1.7 | Nav1.8 | Nav1.9 | Others                                                                 |
|-------|--------|--------|--------|--------|--------|--------|--------|--------|--------|------------------------------------------------------------------------|
| JzTx-34 | 2 | 3 nM   | 7950 nM | 478 nM | 158.6 nM | 188.9 nM | 824 nM |        |        | 610 nM (s, H<sub>T</sub>, h) [119] No inhibition (s, ND cells, h) [119] |
|        |        |        |        |        |        |        |        |        |        | No inhibition in TTX-R currents [119] |
| JzTx-35 | 2 | 323 nM | 888 nM | 3 nM   | 478 nM | >10,000 nM | >10,000 nM | >10,000 nM | >10,000 nM | >10,000 nM | 55% block (n, H, h, FLIPR) [110] |
|        |        |        |        |        |        |        |        |        |        | 85 nM (rec, TTX-S currents, rat DRG); No inhibition in TTX-R currents [118] |
|        |        |        |        |        |        |        |        |        |        | 91 nM (s, TTX-S currents, rat DRG); No inhibition in TTX-R currents [119] |
| CcoTx-1 | 1 | 523 nM | 3 nM   | 888 nM | 323 nM | 5120 nM | >10,000 nM | >10,000 nM | >10,000 nM | >10,000 nM | 55% block (n, H, h, FLIPR) [110] |
|        |        |        |        |        |        |        |        |        |        | 85 nM (rec, TTX-S currents, rat DRG); No inhibition in TTX-R currents [118] |
|        |        |        |        |        |        |        |        |        |        | 91 nM (s, TTX-S currents, rat DRG); No inhibition in TTX-R currents [119] |
Table A1. Cont.

| Toxin       | NaSpTx Family | Nav1.1        | Nav1.2        | Nav1.3        | Nav1.4        | Nav1.5        | Nav1.6        | Nav1.7        | Nav1.8        | Nav1.9        | Others       |
|-------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|--------------|
| CcoTx-2     |               | 407 nM (n, X) [73] | 8 nM (n, X) [73] | 88 nM (n, X) [73] | 400 nM (n, X) [73] | 1634 nM (n, X) [73] | 3990 nM (n, H, h, FLIPR) [110] | 230 nM (n, H, h, FLIPR) [110] | >10,000 nM (n, H, h, FLIPR) [110] | 40% block (n, X) [73] |             |
|             |               | 170 nM (n, H, h, FLIPR) [110] | 80 nM (n, H, h, FLIPR) [110] | 5570 nM (n, H, h, FLIPR) [110] | >10,000 nM (n, H, h, FLIPR) [110] | >10,000 nM (n, H, h, FLIPR) [110] | >10,000 nM (n, H, h, FLIPR) [110] |             |               |               |             |
| CcoTx-3     | 2             | No activity [73] | No activity [73] | No activity [73] | No activity [73] | 447 nM (n, X) [73] | 45% block (n, X) [73] |             |             |               |             |
| PaurTx3     | 1             | 610 nM (n, X) [73] | 0.6 nM (n, X) [73] | 42 nM (n, X) [73] | 288 nM (n, X) [73] | 72 nM (n, X) [73] | 65% block (n, X) [73] |             |             |               |             |
| Hm-1        | 9             | 32.4% block at 200 nM (n, X, r) [120] | 36.5% block at 200 nM (n, X, h) [120] | 38.7% block at 200 nM (n, X, m) [120] |             |             |             |             |             |             |
|             |               | 154.8 nM (n, X, r) [120] |             |             |             |             |             |             |             |               |             |
| Hm-2        | 9             | 64.6% block at 200 nM (n, X, r) [120] | 61.9% block at 200 nM (n, X, h) [120] | 17.8% block at 200 nM (n, X, m) [120] |             |             |             |             |             |             |
|             |               | 120 nM (s, H, h) [239] |             |             |             |             |             |             |             |               |             |
| GTx1-15     | 1             | 120 nM (s, H, h) [239] | No effect up to 2000 nM (s, H, h) [239] | 7 nM (s, H, h) [239] | No effect up to 930 nM (s, H, h) [239] |             |             |             |             |             |             |
| Toxin | NaSpTx Family | Nav1.1 | Nav1.2 | Nav1.3 | Nav1.4 | Nav1.5 | Nav1.6 | Nav1.7 | Nav1.8 | Nav1.9 | Others |
|-------|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| VSTx-3 | 1 | 190 nM (s, H, h) [239] | | | | 430 nM (s, H, h) [239] | 770 nM (s, H, h) [239] |
| Hd1a | 1 | 87% block (rec, X, h) [121] | 55% block (rec, X, h) [121] | 23%–31% block (rec, X, h) [121] | 23%–31% block (rec, X, h) [121] | No inhibition up to 1000 nM (rec, X, h) [121] | 111 nM (rec, X, h) [121] | No inhibition up to 1000 nM (rec, X, h) [121] |
| Cd1a | 1 | 2180 µM (s, H, h, FLIPR) [110] | 130 µM (s, H, h, FLIPR) [110] | >30,000 nM (s, H, h, FLIPR) [110] | >30,000 nM (s, H, h, FLIPR) [110] | >30,000 nM (s, H, h, FLIPR) [110] | >30,000 nM (s, H, h, FLIPR) [110] | 3340 nM (s, H, h, FLIPR) [110] | 6920 nM (s, H, h, FLIPR) [110] | |
| Pre1a | 1 | 57.1 nM (s, H, h) [111] | 189.6 nM (s, X, r) [111] | 8000 nM (s, X, r) [111] | 16.5% block at 1000 nM (s, X, r) [111] | 8.6% block at 1000 nM (s, X, r) [111] | 221.6 nM (s, H, h) [111] | 114 nM (s, X, r) [111] | 15 nM (s, H, h) [111] | |
| Pn3a | 2 | 37 nM (s, H, h) [61] | 124 nM (s, H, h) [61] | 210 nM (s, H, h) [61] | 144 nM (s, H, h) [61] | 800 nM (s, H, h) [61] | 129 nM (s, H, h) [61] | 0.9 nM (s, H, h) [61] | 1.5 nM (s, H, r) [61] | 50,000 nM (s, H, h) [61] | 2427 nM (s, H, h) [61] |

Table A1. Cont.
| Toxin                  | NaSpTx Family | Nav1.1 | Nav1.2 | Nav1.3 | Nav1.4 | Nav1.5 | Nav1.6 | Nav1.7 | Nav1.8 | Nav1.9 | Others                        |
|-----------------------|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------------------------------|
| Hl1a                  | 7             | No inhibition (s, H<sub>T</sub>, h) [123] | No inhibition (s, H<sub>T</sub>, h) [123] | No inhibition (s, H<sub>T</sub>, h) [123] | No inhibition (s, H<sub>T</sub>, h) [123] | No inhibition (s, H<sub>T</sub>, h) [123] | 2190 nM (s, ND7/23 cell, h) [123] | 3760 nM (s, rat DRG) [123] |
| GpTx-1                | 1             | 6000 nM (s, H, h, FLIPR) [122] | 5000 nM (s, H, h, FLIPR) [122] | 20 nM (s, C, h) [76] | 301 nM (s, H, h, Manual ephys) [76] | 4200 nM (s, H, h, Manual ephys) [76] | 17,000 nM (s, H, h, PatchXpress) [122] | 12,200 nM (s, C, h, FLIPR) [122] | 580 nM (s, H, h, FLIPR) [122] | 12,000 nM (s, H, h, FLIPR) [122] | 8 nM, open/inactivated state; 13 nM, closed/resting state (s, C, h) [122] |
| F5A-M6F-T26L-K28R-GpTx-1 | 1          | 1900 nM (s, H, h, PatchXpress) [76] | 1.6 nM (s, H, h, PatchXpress) [76] | 1.6 nM (s, H, h, PatchXpress) [76] | 326,000 nM (s, H, h, FLIPR) [122] | 140,000 nM (s, H, h, FLIPR) [122] | }
## Table A1. Cont.

| Toxin | NaSpTx Family | Nav1.1 | Nav1.2 | Nav1.3 | Nav1.4 | Nav1.5 | Nav1.6 | Nav1.7 | Nav1.8 | Nav1.9 | Others |
|-------|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Df1a  | 2             | 14.3 nM, s-NH₂; 30.7 nM, s-OH; (H, h) [92] | 1.9 nM, s-NH₂; 3 nM, s-OH; (H, h) [92] | 3 nM, s-NH₂; 10 nM, s-OH; (H, h) [92] | 24 nM, s-NH₂; 53.6 nM, s-OH; (H, h) [92] | 45.3 nM, s-NH₂; 125.6 nM, s-OH; (H, h) [92] | 7.6 nM, s-NH₂; 23 nM, s-OH; (C, h) [92] | 1.9 nM, s-NH₂; 60.5 nM, s-OH; (H, h) [92] |
| Phlo1a| 2             | 459 nM (n, X, h) [240] | 218 nM (n, X, h) [240] | 333 nM (n, X, h) [240] |
| Phlo1b| 2             | 459 nM (n, X, h) [240] | 218 nM (n, X, h) [240] | 333 nM (n, X, h) [240] |
| Phlo2a| 3             | 630 nM (n, H, h) [241] | 230 nM (n, H, h) [241] | 770 nM (n, H, h) [241] | 1290 nM (n, Hₜ, h) [241] | ~22,000 nM (n, H, h) [241] | 630 nM (n, H, h) [241] | 370 nM (n, Hₜ, h) [241] |
| GrTx-1| 3             | 5700 nM (n, H, h) [241] | 12,000 nM (n, H, h) [241] | 24,000 nM (n, H, h) [241] | 4000 nM (n, Hₜ, h) [241] | ~42,000 nM (n, H, h) [241] | 6600 nM (n, H, h) [241] | 1030 nM (n, Hₜ, h) [241] |

Note: s- synthetic; n- native; rec- recombinantly expressed; rec-G- recombinantly expressed with an extra N-terminal Glycine; s-OH- synthetic free carboxyl end; s-NH₂- synthetic C-terminal amidated; H- HEK 293 cells; Hₜ- transiently transfected HEK 293 cells; X- *Xenopus* oocytes; C- CHO cells; S- SHSY5Y cells; h- human Naᵥ; r- rat Naᵥ; m- mouse Naᵥ; r- rat Naᵥ; M- mammalian Naᵥ; FLIPR- Fluorescence Imaging Plate Reader.
**Table A2.** Excitatory effects of spider knottins on Na\(_V\) channel subtypes. Values presented were obtained from electrophysiological experiments, unless otherwise as stated.

| Toxin  | NaSpTx Family | Na\(_V\)1.1 | Na\(_V\)1.2 | Na\(_V\)1.3 | Na\(_V\)1.4 | Na\(_V\)1.5 | Na\(_V\)1.6 | Na\(_V\)1.7 | Na\(_V\)1.8 | Na\(_V\)1.9 | Others |
|--------|---------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|---------|
| JzTx-I | 7             |             | 870 nM \((n, H_T, r)\) \[100\] | 845 nM \((n, H_T, r)\) \[100\] | 399 nM \((n, H_T, r)\) \[100\] | 355 nM \((n, H_T, r)\) \[100\] | 348 nM \((n, H_T, r)\) \[100\] | 130 nM \((n, TTX-S currents, rat DRG); No inhibition in rat DRG TTX-R currents; 31 nM in rat cardiac myocytes) \[101\] |
|        |               |             |             |             |             |             |             |             |             |             |         |
| JzTx-II| 7             |             | 1650 nM \((n, H_T, r)\) \[98\] |             |             |             |             |             |             |             |         |
|        |               |             |             |             |             |             |             |             |             |             |         |
| Hm1a   | 2             |             | 38 nM \((s, X, h)\) \[20\] | 236 nM \((s, X, h)\) \[20\] | 220 nM \((s, X, h)\) \[20\] | No inhibition up to 1000 nM \((s, X, h)\) \[20\] | No inhibition up to 1000 nM \((s, X, h)\) \[20\] | No inhibition up to 1000 nM \((s, X, h)\) \[20\] | No inhibition up to 1000 nM \((s, X, h)\) \[20\] | No inhibition up to 1000 nM \((s, X, h)\) \[20\] |         |
| PnTx2-1| 6             |             | 122 nM \((n, X, r)\) \[147\] | No inhibition up to 1000 nM \((n, X, r)\) \[147\] | No inhibition up to 1000 nM \((n, X, r)\) \[147\] | 87 nM \((n, X, h)\) \[147\] | No inhibition up to 1000 nM \((n, X, h)\) \[147\] | 101.1 nM \((n, X, r)\) \[147\] | No inhibition up to 1000 nM \((n, X, m)\) \[147\] |         |

Note: \(s\): synthetic; \(n\): native; \(H_T\): transiently transfected HEK 293 cells; \(X\): *Xenopus* oocytes; \(h\): human Na\(_V\); \(r\): rat Na\(_V\); \(r\): rat Na\(_V\).
References

1. Nicholson, G.M. Spider Peptides. In Handbook of Biologically Active Peptides, 2nd ed.; Kastin, A.J., Ed.; Academic Press: Boston, MA, USA, 2013; pp. 461–472. [CrossRef]

2. Catalog, W.S. World Spider Catalog. Available online: https://wsc.nmbe.ch/statistics/ (accessed on 25 June 2019).

3. Caddington, J.; Levi, H. Systematic and evolution of spiders (Araenea). Annu. Rev. Ecol. Syst. 1991, 22, 565–592. [CrossRef]

4. King, G.F.; Hardy, M.C. Spider-venom peptides: Structure, pharmacology, and potential for control of insect pests. Annu. Rev. Entomol. 2013, 58, 475–496. [CrossRef] [PubMed]

5. Samiayyan, K. Spiders—The generalist super predators in agro-ecosystems. In Integrated Pest Management; Elsevier: San Diego, CA, USA, 2014; pp. 283–310. [CrossRef]

6. Cooper, A.M.; Nelsen, D.R.; Hayes, W.K. The Strategic Use of Venom by Spiders. In Evolution of Venomous Animals and Their Toxins; Malhotra, A., Ed.; Springer: Dordrecht, The Netherlands, 2017; pp. 145–166. [CrossRef]

7. Dongol, Y.; Dhananjaya, B.L.; Shrestha, R.K.; Aryal, G. Animal Venoms and Nephrotoxic Effects. In Clinical Toxinology in Australia, Europe, and Americas. Toxinology; Gopalakrishnakone, P., Vogel, C.-W., Seifert, S.A., Tambourgi, D.V., Eds.; Springer: Dordrecht, The Netherlands, 2018; pp. 539–556. [CrossRef]

8. Zlotkin, E. The insect voltage-gated sodium channel as target of insecticides. Annu. Rev. Entomol. 1999, 44, 429–455. [CrossRef] [PubMed]

9. Billen, B.; Vassilevski, A.; Nikolsky, A.; Debaveye, S.; Tytgat, J.; Grishin, E. Unique bell-shaped voltage-dependent modulation of Na+ channel gating by novel insect-selective toxins from the spider Agelena orientalis. J. Biol. Chem. 2010, 285, 18545–18554. [CrossRef] [PubMed]

10. Escoubas, P.; Sollod, B.; King, G.F. Venom landscapes: Mining the complexity of spider venoms via a combined cDNA and mass spectrometric approach. Toxicon 2006, 47, 650–663. [CrossRef]

11. Sannaningaiah, D.; Subbaiah, G.K.; Kempaiah, K. Pharmacology of spider venom toxins. Toxin Rev. 2014, 33, 206–220. [CrossRef]

12. Pineda, S.S.; Undheim, E.A.; Rupasinghe, D.B.; Ikonomopoulou, M.P.; King, G.F. Spider venomics: Implications for drug discovery. Future Med. Chem. 2014, 6, 1699–1714. [CrossRef]

13. Escoubas, P.; Diochot, S.; Corzo, G. Structure and pharmacology of spider venom neurotoxins. Biochimie 2000, 82, 893–907. [CrossRef]

14. Cardoso, F.C.; Lewis, R.J. Structure–Function and therapeutic potential of spider venom-derived cysteine knot peptides targeting sodium channels. Front. Pharmacol. 2019, 10. [CrossRef]

15. Klint, J.K.; Sensf, S.; Rupasinghe, D.B.; Er, S.Y.; Herzig, V.; Nicholson, G.M.; King, G.F. Spider-venom peptides that target voltage-gated sodium channels: Pharmacological tools and potential therapeutic leads. Toxicon 2012, 60, 478–491. [CrossRef]

16. Stevens, M.; Peigneur, S.; Tytgat, J. Neurotoxins and their binding areas on voltage-gated sodium channels. Front. Pharmacol. 2011, 2, 71. [CrossRef] [PubMed]

17. Wu, Y.; Ma, H.; Zhang, F.; Zhang, C.; Zou, X.; Cao, Z. Selective voltage-gated sodium channel peptide toxins from animal venom: Pharmacological probes and analgesic drug development. ACS Chem. Neurosci. 2018, 9, 187–197. [CrossRef] [PubMed]

18. Kalia, J.; Milescu, M.; Salvatierra, J.; Wagner, J.; Klint, J.K.; King, G.F.; Olivera, B.M.; Bosmans, F. From foe to friend: Using animal toxins to investigate ion channel function. J. Mol. Biol. 2015, 427, 158–175. [CrossRef] [PubMed]

19. Salvatierra, J.; Castro, J.; Erickson, A.; Li, Q.; Braz, J.; Gilchrist, J.; Grundy, L.; Rychkov, G.Y.; Deiteren, A.; Rais, R. Nav1.1 inhibition can reduce visceral hypersensitivity. JCI Insight 2018, 3. [CrossRef]

20. Osteen, J.D.; Herzig, V.; Gilchrist, J.; Emrick, J.J.; Zhang, C.; Wang, X.; Castro, J.; Garcia-Caraballo, S.; Grundy, L.; Rychkov, G.Y.; et al. Selective spider toxins reveal a role for the Nav1.1 channel in mechanical pain. Nature 2016, 534, 494–499. [CrossRef]

21. Cardoso, F.C.; Lewis, R.J. Sodium channels and pain: From toxins to therapies. Br. J. Pharmacol. 2018, 175, 2138–2157. [CrossRef]

22. Lukowski, A.L.; Narayan, A.R.H. Natural voltage-gated sodium channel ligands: Biosynthesis and Biology. ChemBioChem 2019, 20, 1231–1241. [CrossRef]
23. Black, J.A.; Waxman, S.G. Noncanonical roles of voltage-gated sodium channels. *Neuron* 2013, 80, 280–291. [CrossRef]

24. Yamamoto, R.; Yanagita, T.; Kobayashi, H.; Yokoo, H.; Wada, A. Up-regulation of sodium channel subunit mRNAs and their cell surface expression by antiepileptic valproic acid: Activation of calcium channel and catecholamine secretion in adrenal chromaffin cells. *J. Neurochem.* 1997, 68, 1655–1662. [CrossRef]

25. Andrikopoulos, P.; Fraser, S.P.; Patterson, L.; Ahmad, Z.; Burcu, H.; Ottaviani, D.; Diss, J.K.; Box, C.; Eccles, S.A.; Djamgoz, M.B. Angiogenic functions of voltage-gated Na⁺ Channels in human endothelial cells: Modulation of vascular endothelial growth factor (VEGF) signaling. *J. Biol. Chem.* 2011, 286, 16846–16860. [CrossRef]

26. Carrithers, M.D.; Dib-Hajj, S.; Carrithers, L.M.; Tokmoulina, G.; Pypaert, M.; Jonas, E.A.; Waxman, S.G. Expression of the voltage-gated sodium channel Nav1.5 in the macrophage late endosome regulates endosomal acidification. *J. Immunol.* 2007, 178, 7822–7832. [CrossRef] [PubMed]

27. Carrithers, M.D.; Chatterjee, G.; Carrithers, L.M.; Offoha, R.; Iheagwara, U.; Rahner, C.; Graham, M.; Waxman, S.G. Regulation of podosome formation in macrophages by a splice variant of the sodium channel SCN8A. *J. Biol. Chem.* 2009, 284, 8114–8126. [CrossRef] [PubMed]

28. Pucca, M.B.; Peigneur, S.; Cologna, C.T.; Cerni, F.A.; Zoccal, K.F.; Bordon, K.D.C.F.; Faccioli, L.H.; Tytgat, J.; Eccles, S.A.; Djamgoz, M.B. Regulation of voltage-gated sodium channel expression in cancer: Hormones, growth factors and auto-regulation. *Philos. Trans. R. Soc. B Biol. Sci.* 2014, 369. [CrossRef] [PubMed]

29. Fraser, S.P.; Ozerlat-Gunduz, I.; Brackenbury, W.J.; Fitzgerald, E.M.; Campbell, T.M.; Coombes, R.C.; Coombes, R.C.; Djamgoz, M.B.A. Regulation of voltage-gated sodium channel expression in cancer: Hormones, growth factors and auto-regulation. *Philos. Trans. R. Soc. B Biol. Sci.* 2014, 369. [CrossRef] [PubMed]

30. Waxman, S.G. Axonal conduction and injury in multiple sclerosis: The role of sodium channels. *Nat. Rev. Neurosci.* 2006, 7, 932–941. [CrossRef] [PubMed]

31. Kaplan, D.I.; Isom, L.; Petrov, S. 17. Role of Sodium Channels in Epilepsy. *Cold Spring Harb. Perspect. Med.* 2016, 6. [CrossRef]

32. Raouf, R.; Quick, K.; Wood, J.N. Pain as a channelopathy. *J. Clin. Investig.* 2010, 120, 3745–3752. [CrossRef]

33. Dib-Hajj, S.D.; Waxman, S.G. Sodium channels in human pain disorders: Genetics and pharmacogenomics. *Annu. Rev. Neurosci.* 2019, 42. [CrossRef]

34. Savio Galimberti, E.; Gollob, M.; Darbar, D. Voltage-gated sodium channels: Biophysics, pharmacology, and related channelopathies. *Front. Pharmacol.* 2012, 3. [CrossRef]

35. Probst, V.; Kynadt, F.; Potet, F.; Trochu, J.N.; Mialet, G.; Demolombe, S.; Schott, J.J.; Baro, I.; Escande, D.; Le Marec, H. Haploinsufficiency in combination with aging causes SCN5A-linked hereditary Lenegre disease. *J. Am. Coll. Cardiol.* 2003, 41, 643–652. [CrossRef]

36. Cox, J.J.; Reimann, F.; Nicholas, A.K.; Thornton, G.; Roberts, E.; Springell, K.; Karbani, G.; Jafri, H.; Mannan, J.; Raashid, Y. An SCN9A channelopathy causes congenital inability to experience pain. *Nature* 2006, 444, 894. [CrossRef]

37. Claes, L.; Del-Favero, J.; Ceulemans, B.; Lagae, L.; van Broeckhoven, C.; de Jonghe, P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. *Am. J. Hum. Genet.* 2001, 68, 1327–1332. [CrossRef] [PubMed]

38. Mantegazza, M.; Gambardella, A.; Rusconi, R.; Schiavon, E.; Annesi, F.; Cassulini, R.R.; Labate, A.; Carrideo, S.; Chifari, R.; Canevini, M.P.; et al. Identification of an Nav1.1 sodium channel (SCN1A) loss-of-function mutation associated with familial simple febrile seizures. *Proc. Natl. Acad. Sci. USA* 2005, 102, 18177–18182. [CrossRef] [PubMed]

39. Shen, H.; Zhou, Q.; Pan, X.; Li, Z.; Wu, J.; Yan, N. Structure of a eukaryotic voltage-gated sodium channel at near-atomic resolution. *Science* 2017, 355, eaal4326. [CrossRef] [PubMed]

40. Patino, G.A.; Brackenbury, W.J.; Bao, Y.; Lopez-Santiago, L.F.; O’Malley, H.A.; Chen, C.; Calhoun, J.D.; Lafrenière, R.G.; Cossette, P.; Rouleau, G.A. Voltage-gated Na⁺ channel β1B: A secreted cell adhesion molecule involved in human epilepsy. *J. Neurosci.* 2011, 31, 14577–14591. [CrossRef]

41. O’Malley, H.A.; Isom, L.L. Sodium channel β subunits: Emerging targets in channelopathies. *Annu. Rev. Physiol.* 2015, 77, 481–504. [CrossRef]

42. Patino, G.A.; Isom, L.L. Electrophysiology and beyond: Multiple roles of Na⁺ channel β subunits in development and disease. *Neurosci. Lett.* 2010, 486, 53–59. [CrossRef]
68. Pallaghy, P.K.; Nielsen, K.J.; Craik, D.J.; Norton, R.S. A common structural motif incorporating a cystine knot and a triple-stranded β-sheet in toxic and inhibitory polypeptides. *Protein Sci.* 1994, 3, 1833–1839. [CrossRef] [PubMed]

69. Postic, G.; Gracy, J.; Périn, C.; Chiche, L.; Gelly, J.-C. KNOTTIN: The database of inhibitor cystine knot scaffold after 10 years, toward a systematic structure modeling. *Nucleic Acids Res.* 2017, 46, D454–D458. [CrossRef] [PubMed]

70. Craik, D.J.; Daly, N.L.; Waine, C. The cystine knot motif in toxins and implications for drug design. *Toxicon* 2001, 39, 43–60. [CrossRef]

71. Saez, N.J.; Senff, S.; Jensen, J.E.; Er, S.Y.; Herzig, V.; Rash, L.D.; King, G.F. Spider-venom peptides as therapeutics. *Toxins* 2010, 2, 2851–2871. [CrossRef] [PubMed]

72. Agwa, A.J.; Huang, Y.H.; Craik, D.J.; Henriques, S.T.; Schroeder, C.I. Lengths of the C-terminus and interconnecting loops impact stability of spider-derived gating modifier toxins. *Toxins* 2017, 9, 248. [CrossRef]

73. Bosmans, F.; Rash, L.; Zhu, S.; Diochot, S.; Lazdunski, M.; Escoubas, P.; Tytgat, J. Four novel tarantula toxins select as selective modulators of voltage-gated sodium channel subtypes. *Mol. Pharmacol.* 2006, 69, 419–429. [CrossRef]

74. Wang, J.M.; Roh, S.H.; Kim, S.; Lee, C.W.; Kim, J.I.; Swartz, K.J. Molecular surface of tarantula toxins interacting with voltage sensors in Kv channels. *J. Gen. Physiol.* 2004, 123, 455–467. [CrossRef]

75. Lawrence, N.; Wu, B.; Ligutti, J.; Cheneval, O.; Agwa, A.J.; Benfield, A.H.; Biswas, K.; Craik, D.J.; Miranda, L.P.; Henriques, S.T. Peptide-membrane interactions affect the inhibitory potency and selectivity of spider toxins ProTx-II and GpTx-1. *ACS Chem. Biol.* 2018, 14, 118–130. [CrossRef]

76. Murray, J.K.; Ligutti, J.; Liu, D.; Zou, A.; Poppe, L.; Li, H.; Andrews, K.L.; Moyer, B.D.; McDonough, S.I.; Favreau, P. Engineering potent and selective analogues of GpTx-1, a tarantula venom peptide antagonist of the Nav.1.7 sodium channel. *J. Med. Chem.* 2015, 58, 2299–2314. [CrossRef] [PubMed]

77. Smith, J.J.; Cummins, T.R.; Alphy, S.; Blumenthal, K.M. Molecular interactions of the gating modifier toxin, ProTx-II, with Na.1.5: Implied existence of a novel toxin binding site coupled to activation. *J. Biol. Chem.* 2007. [CrossRef] [PubMed]

78. Liu, Y.; Li, D.; Wu, Z.; Li, J.; Nie, D.; Xiang, Y.; Liu, Z. A positively charged surface patch is important for hainantoxin-IV binding to voltage-gated sodium channels. *J. Pept. Sci.* 2012, 18, 643–649. [CrossRef] [PubMed]

79. Luo, J.; Zhang, Y.; Gong, M.; Lu, S.; Ma, Y.; Zeng, X.; Liang, S. Molecular surface of JZTX-V (β-Theraphotoxin-Cj2a) interacting with voltage-gated sodium channel subtype Na.1.4. *Toxins* 2014, 6, 2177–2193. [CrossRef] [PubMed]

80. Cardoso, F.C.; Dekan, Z.; Rosengren, K.J.; Erickson, A.; Vetter, I.; Deuis, J.; Herzig, V.; Alewood, P.; King, G.F.; Lewis, R.J. Identification and characterization of ProTx-III [μ-TRTX-Tp1a], a new voltage-gated sodium channel inhibitor from venom of the tarantula *Thrixopelma pruriens*. *Mol. Pharmacol.* 2015, 88, 291–303. [CrossRef]

81. Klint, J.K.; Chin, Y.K.; Mobli, M. Rational engineering defines a molecular switch that is essential for activity of spider-venom peptides against the analgesics target Na.1.7. *Mol. Pharmacol.* 2015, 88, 1002–1010. [CrossRef]

82. Henriques, S.T.; Deplazes, E.; Lawrence, N.; Cheneval, O.; Chaousis, S.; Inserra, M.; Thongyoo, P.; King, G.F.; Mark, A.E.; Vetter, I.; et al. Interaction of tarantula venom peptide ProTx-II with lipid membranes is a prerequisite for its inhibition of human voltage-gated sodium channel Na.1.7. *J. Biol. Chem.* 2016, 291, 17049–17065. [CrossRef]

83. Minassian, N.A.; Gibbs, A.; Shih, A.Y.; Liu, Y.; Neff, R.A.; Sutton, S.W.; Mirzadeegan, T.; Connor, J.; Fellows, R.; Husovsky, M. Analysis of the structural and molecular basis of voltage-sensitive sodium channel inhibition by the spider toxin huwentoxin-IV (μ-TRTX-Hh2a). *J. Biol. Chem.* 2013, 288, 22707–22720. [CrossRef]

84. The UniProt Consortium. UniProt: A worldwide hub of protein knowledge. *Nucleic Acids Res.* 2018, 47, D506–D515. [CrossRef]

85. Li, D.; Xiao, Y.; Xu, X.; Xiong, X.; Lu, S.; Liu, Z.; Zhu, Q.; Wang, M.; Gu, X.; Liang, S. Structure-activity relationships of hainantoxin-IV and structure determination of active and inactive sodium channel blockers. *J. Biol. Chem.* 2004, 279, 37734–37740. [CrossRef]

86. Agwa, A.J.; Peigneur, S.; Chow, C.Y.; Lawrence, N.; Craik, D.J.; Tytgat, J.; King, G.F.; Henriques, S.T.; Schroeder, C.I. Gating modifier toxins isolated from spider venom: Modulation of voltage-gated sodium channels and the role of lipid membranes. *J. Biol. Chem.* 2018, 293, 9041–9052. [CrossRef] [PubMed]
87. Fontana, M.; Vital-Brazil, O. Mode of action of Phoneutria nigriventer spider venom at the isolated phrenic nerve-diaphragm of the rat. Braz. J. Med. Biol. Res. 1985, 18, 557–565. [PubMed]

88. Rezende, L., Jr.; Cordeiro, M.N.; Oliveira, E.B.; Diniz, C.R. Isolation of neurotoxic peptides from the venom of the ‘armed’ spider Phoneutria nigriventer. Toxicon 1991, 29, 1225–1233. [CrossRef]

89. Araújo, D.A.; Cordeiro, M.N.; Diniz, C.R.; Beirão, P.S. Effects of a toxic fraction, PhTx 2, from the spider Phoneutria nigriventer on the skeletal muscle. Naunyn Schmiedeberg’s Arch. Pharmacol. 1993, 347, 205–208. [CrossRef] [PubMed]

90. Adams, M.E.; Herold, E.E.; Venema, V.J. Two classes of channel-specific toxins from funnel web spider venom. J. Comp. Physiol. A Neuroethol. Sen. Neural. Behav. Physiol. 1989, 164, 333–342. [CrossRef] [PubMed]

91. Tang, C.; Zhou, X.; Huang, Y.; Zhang, Y.; Hu, Z.; Wang, M.; Chen, P.; Liu, Z.; Liang, S. The tarantula toxin jingzhaotoxin-XI (α-theraphotoxin-Cj1α) regulates the activation and inactivation of the voltage-gated sodium channel Nav1.5. Toxicon 2014, 92, 6–13. [CrossRef]

92. Cardoso, F.C.; Dekan, Z.; Smith, J.J.; Deuis, J.R.; Vetter, I.; Herzig, V.; Alewood, P.F.; King, G.F.; Lewis, R.J. Modulatory features of the novel spider toxin µ-TKTX-Df1a isolated from the venom of the spider Davus fasciatus. Br. J. Pharmacol. 2017, 174, 2528–2544. [CrossRef]

93. Matavel, A.; Cruz, J.S.; Penaforte, C.L.; Araújo, D.A.; Kalapothakis, E.; Prado, V.F.; Diniz, C.R.; Cordeiro, M.N.; Beirão, P.S. Electrophysiological characterization and molecular identification of the Phoneutria nigriventer peptide toxin PnTx2-6. FEBS Lett. 2002, 523, 219–223. [CrossRef]

94. Nicholson, G.M.; Little, M.J.; Tyler, M.; Narahashi, T. Selective alteration of sodium channel gating by Australian funnel-web spider toxins. Toxicon 1996, 34, 1443–1453. [CrossRef]

95. Little, M.J.; Zappia, C.; Gilles, N.; Connor, M.; Tyler, M.I.; Martin-Eauclaire, M.-F.; Gordon, D.; Nicholson, G.M. δ-Atracotoxins from Australian funnel-web spiders compete with scorpion α-toxin binding but differentially modulate alkaloid toxin activation of voltage-gated sodium channels. J. Biol. Chem. 1998, 273, 27076–27083. [CrossRef]

96. Nicholson, G.M.; Walsh, R.; Little, M.J.; Tyler, M.I. Characterisation of the effects of robustoxin, the lethal neurotoxin from the Sydney funnel-web spider Atrax robustus, on sodium channel activation and inactivation. Pflügers Archiv 1998, 436, 117–126. [CrossRef] [PubMed]

97. Szeto, T.H.; Birininyi-Strachan, L.C.; Smith, R.; Connor, M.; Christie, M.J.; King, G.F.; Nicholson, G.M. Isolation and pharmacological characterisation of δ-atracotoxin-Hv1b, a vertebrate-selective sodium channel toxin. FEBS Lett. 2000, 470, 293–299. [CrossRef]

98. Huang, Y.; Zhou, X.; Tang, C.; Zhang, Y.; Tao, H.; Chen, P.; Liu, Z. Molecular basis of the inhibition of the fast inactivation of voltage-gated sodium channel NaV1.5 by tarantula toxin Jingzhaotoxin-II. Peptides 2015, 68, 175–182. [CrossRef] [PubMed]

99. Nicholson, G.M.; Willow, M.; Howden, M.E.; Narahashi, T. Modification of sodium channel gating and kinetics by versutoxin from the Australian funnel-web spider Hadronyche versuta. Pflügers Archiv 1994, 428, 400–409. [CrossRef] [PubMed]

100. Tao, H.; Chen, X.; Lu, M.; Wu, Y.; Deng, M.; Zeng, X.; Liu, Z.; Liang, S. Molecular determinant for the tarantula toxin jingzhaotoxin-I slowing the fast inactivation of voltage-gated sodium channels. Toxicon 2016, 111, 13–21. [CrossRef] [PubMed]

101. Xiao, Y.; Tang, J.; Hu, W.; Xie, J.; Maertens, C.; Tytgat, J.; Liang, S. Jingzhaotoxin-I, a novel spider neurotoxin preferentially inhibiting cardiac sodium channel activation. J. Biol. Chem. 2005, 280, 12069–12076. [CrossRef] [PubMed]

102. Xiao, Y.; Li, J.; Deng, M.; Dai, C.; Liang, S. Characterization of the excitatory mechanism induced by Jingzhaotoxin-I inhibiting sodium channel inactivation. Toxicon 2007, 50, 507–517. [CrossRef]

103. Middleton, R.E.; Warren, V.A.; Kraus, R.L.; Hwang, J.C.; Liu, C.J.; Dai, G.; Brochu, R.M.; Kohler, M.G.; Gao, Y.-D.; Garsky, V.M. Two tarantula peptides inhibit activation of multiple sodium channels. Biochemistry 2002, 41, 14734–14747. [CrossRef]

104. Xiao, Y.; Blumenthal, K.M.; Jackson, J.O.; Liang, S.; Cummins, T.R. The tarantula toxins ProTx-II and HwTX-IV differentially interact with human NaV1.7 voltage-sensors to inhibit channel activation and inactivation. Mol. Pharmacol. 2010, 78, 1124–1134. [CrossRef]

105. Xiao, Y.; Tang, J.; Yang, Y.; Wang, M.; Hu, W.; Xie, J.; Zeng, X.; Liang, S. Jingzhaotoxin-III, a novel spider toxin inhibiting activation of voltage-gated sodium channel in rat cardiac myocytes. J. Biol. Chem. 2004, 279, 26220–26226. [CrossRef]
106. Rong, M.; Chen, J.; Tao, H.; Wu, Y.; Jiang, P.; Lu, M.; Su, H.; Chi, Y.; Cai, T.; Zhao, L. Molecular basis of the tarantula toxin jingzhaoxin-III (β-TRTX-Cj3α) interacting with voltage sensors in sodium channel subtype NaV1.5. *FASEB J.* 2011, 25, 3177–3185. [CrossRef] [PubMed]

107. Zeng, X.; Deng, M.; Lin, Y.; Yuan, C.; Pi, J.; Liang, S. Isolation and characterization of jingzhaoxin-V, a novel neurotoxin from the venom of the spider Chilobrachys jingzhao. *Toxicon* 2009, 47, 388–399. [CrossRef] [PubMed]

108. Deng, M.; Kuang, F.; Sun, Z.; Tao, H.; Cai, T.; Zhong, L.; Chen, Z.; Xiao, Y.; Liang, S. Jingzha toxin-IV, a novel gating modifier of both sodium and potassium channels from Chinese tarantula Chilobrachys jingzhao. *Neuropharmacology* 2009, 57, 77–87. [CrossRef] [PubMed]

109. Nikolsky, A.; Billen, B.; Vassilevski, A.; Filkin, S.Y.; Tytgat, J.; Grishin, E. Voltage-gated sodium channels are targets for toxins from the venom of the spider Heriaeus mellottei. *Biochem. Moscow Suppl. Ser. A* 2009, 3, 245–253. [CrossRef]

110. Sousa, S.R.; Wingerd, J.S.; Brust, A.; Bladen, C.; Ragnarsson, L.; Herzig, V.; Deuis, J.R.; Dutertre, S.; Vetter, I.; Zamponi, G.W. Discovery and mode of action of a novel analgesic β-toxin from the African spider Ceratogyrus darlingi. *PLoS ONE* 2017, 12, e0182848. [CrossRef] [PubMed]

111. Wingerd, J.S.; Mozar, C.A.; Ussing, C.A.; Murali, S.S.; Chin, Y.K.; Cristofori-Armstrong, B.; Durek, T.; Gilchrist, J.; Vaughan, C.W.; Bosmans, F.; et al. The tarantula toxin β-β-TRTX-Pre1a highlights the importance of the S1-S2 voltage-sensor region for sodium channel subtype selectivity. *Sci. Rep.* 2017, 7, 974. [CrossRef]

112. Wei, P.; Xu, C.; Wu, Q.; Huang, L.; Liang, S.; Yuan, C. Jingzhaoxin-35, a novel gating modifier toxin targeting both NaV1.5 and Kv2.1 channels. *Toxicon* 2014, 92, 90–96. [CrossRef]

113. Peng, K.; Shu, Q.; Liu, Z.; Liang, S. Function and solution structure of huwentoxin-IV, a potent neuronal tetrodotoxin (TTX)-sensitive sodium channel antagonist from Chinese bird spider Selencosmia huwena. *J. Biol. Chem.* 2002, 277, 47564–47571. [CrossRef]

114. Xiao, Y.; Bingham, J.-P.; Zhu, W.; Moczylowski, E.; Liang, S.; Cummins, T.R. Tarantula huwentoxin-IV inhibits neuronal sodium channels by binding to receptor site 4 and trapping the domain II voltage sensor in the closed configuration. *J. Biol. Chem.* 2008, 283, 27300–27313. [CrossRef]

115. Deng, M.; Luo, X.; Jiang, L.; Chen, H.; Wang, J.; He, H.; Liang, S. Synthesis and biological characterization of synthetic analogs of Huwentoxin-IV (µ-theraphotoxin-Hh2a), a neuronal tetrodotoxin-sensitive sodium channel inhibitor. *Toxicon* 2013, 71, 57–65. [CrossRef]

116. Xiao, Y.; Liang, S. Inhibition of neuronal tetrodotoxin-sensitive Na⁺ channels by two spider toxins: Hainanoxin-III and hainantoxin-IV. *Eur. J. Pharmacol.* 2003, 477, 1–7. [CrossRef]

117. Liu, Z.; Cai, T.; Zhu, Q.; Deng, M.; Li, J.; Zhou, X.; Zhang, F.; Li, D.; Li, J.; Liu, Y. Structure and function of Hainanoxin-III-a selective antagonist of neuronal tetrodotoxin-sensitive voltage-gated sodium channels isolated from the Chinese bird spider Ornithoctonus hainana. *J. Biol. Chem.* 2013, 288, 20392–20403. [CrossRef] [PubMed]

118. Chen, J.; Zhang, Y.; Rong, M.; Zhao, L.; Jiang, L.; Zhang, D.; Wang, M.; Xiao, Y.; Liang, S. Expression and characterization of jingzhaoxin-34, a novel neurotoxin from the venom of the tarantula Chilobrachys jingzhao. *Peptides* 2009, 30, 1042–1048. [CrossRef] [PubMed]

119. Zeng, X.; Li, P.; Chen, B.; Huang, J.; Lai, R.; Liu, J.; Rong, M. Selective closed-state Nav1.7 blocker JZTX-34 exhibits analgesic effects against pain. *Toxins* 2018, 10, 64. [CrossRef] [PubMed]

120. Billen, B.; Vassilevski, A.; Nikolsky, A.; Tytgat, J.; Grishin, E. Two novel sodium channel inhibitors from Heriaeus mellottei spider venom differentially interacting with mammalian channel’s isoforms. *Toxicon* 2008, 52, 309–317. [CrossRef] [PubMed]

121. Klint, J.K.; Smith, J.J.; Vetter, I.; Rupasinghe, D.B.; Er, S.Y.; Senff, S.; Herzig, V.; Mobli, M.; Lewis, R.J.; Bosmans, F. Seven novel modulators of the analgesic target Nav1.7 uncovered using a high-throughput venom-based discovery approach. *Br. J. Pharmacol.* 2015, 172, 2445–2458. [CrossRef] [PubMed]

122. Deuis, J.R.; Wingerd, J.S.; Winter, Z.; Durek, T.; Dekan, Z.; Sousa, S.R.; Zimmermann, K.; Hoffmann, T.; Weidner, C.; Nassar, M.A. Analgesic effects of GpTx-1, PF-04856264 and CNV1014802 in a mouse model of Nav1.7-mediated pain. *Toxins* 2016, 8, 78. [CrossRef]

123. Meng, P.; Huang, H.; Wang, G.; Yang, S.; Lu, Q.; Liu, J.; Lai, R.; Rong, M. A novel toxin from Haplopelma lividum selectively inhibits the Nav1.8 channel and possesses potent analgesic efficacy. *Toxins* 2017, 9, 7. [CrossRef]
124. Martin-Moutot, N.; Mansuelle, P.; Alcaraz, G.; Gouvea dos Santos, R.; Cordeiro, M.N.; De Lima, M.E.; Seagar, M.; van Renterghem, C. *Phoneutria nigriventer* toxin 1: A novel, state-dependent inhibitor of neuronal sodium channels which interacts with micro conotoxin binding sites. *Mol. Pharmacol.* 2006, 69, 1931–1937. [CrossRef]
125. Zhang, J.; Tang, D.; Liu, S.; Hu, H.; Liang, S.; Tang, C.; Liu, Z. Purification and characterization of JZTx-14, a potent antagonist of mammalian and prokaryotic voltage-gated sodium channels. *Toxins* 2018, 10, 408. [CrossRef]
126. Paiva, A.L.; Matavel, A.; Peigneur, S.; Cordeiro, M.N.; Tytgat, J.; Diniz, M.R.; de Lima, M.E. Differential effects of the recombinant toxin PnTx4(5-5) from the spider *Phoneutria nigriventer* on mammalian and insect sodium channels. *Biochimie* 2016, 121, 326–335. [CrossRef] [PubMed]
127. Liu, Y.; Tang, J.; Zhang, Y.; Xun, X.; Tang, D.; Peng, D.; Yi, J.; Liu, Z.; Shi, X. Synthesis and analgesic effects of μ-TRTX-Hhn1b on models of inflammatory and neuropathic pain. *Toxins* 2014, 6, 2363–2378. [CrossRef] [PubMed]
128. King, G.F.; Escoubas, P.; Nicholson, G.M. Peptide toxins that selectively target insect NaV and Cav channels. *Channels* 2008, 2, 100–116. [PubMed]
129. Cai, T.; Luo, J.; Meng, E.; Ding, J.; Liang, S.; Wang, S.; Liu, Z. Mapping the interaction site for the tarantula toxin hainantoxin-IV (β-TRTX-Hn2a) in the voltage sensor module of domain II of voltage-gated sodium channels. *Peptides* 2015, 68, 148–156. [CrossRef]
130. Cai, T.; Luo, J.; Meng, E.; Ding, J.; Liang, S.; Wang, S.; Liu, Z. Mapping the interaction sites for the tarantula toxin hainantoxin-IV (β-TRTX-Hn2a) in the voltage sensor module of domain II of voltage-gated sodium channels. *Peptides* 2015, 68, 148–156. [CrossRef]
131. Swartz, K.J.; MacKinnon, R. Mapping the receptor site for hanatoxin, a gating modifier of voltage-dependent potassium channels. *J. Gen. Physiol.* 2000, 116, 637–644. [CrossRef]
132. Schmalhofer, W.; Calhoun, J.; Burrows, R.; Bailey, T.; Kohler, M.G.; Weinglass, A.B.; Kaczorowski, G.J.; Garcia, M.L.; Koltzenburg, M.; Priest, B.T. ProTx-II, a selective inhibitor of NaV.1.7 sodium channels, blocks action potential propagation in nociceptors. *Mol. Pharmacol.* 2008, 74, 1476–1484. [CrossRef]
133. Corzo, G.; Gilles, N.; Satake, H.; Villegas, E.; Dai, L.; Nakajima, T.; Haupt, J. Distinct primary structures of the major peptide toxins from the venom of the spider *Macrothele gigas* that bind to sites 3 and 4 in the sodium channel. *FEBS Lett.* 2003, 547, 43–50. [CrossRef]
134. Winterfield, J.R.; Swartz, K.J. A hot spot for the interaction of gating modifier toxins with voltage-dependent ion channels. *J. Gen. Physiol.* 2000, 116, 637–644. [CrossRef]
135. Gonzalez, T.C.; Benoit, E.; Partiseti, M.; Servent, D. The NaV1.7 Channel subtype as an antinociceptive target for spider toxins in adult dorsal root ganglia neurons. *Front. Pharmacol.* 2018, 9. [CrossRef]
136. Schuberbatko, A.; Oto, F.; Mandel, G.; Brehm, P. Voltage-dependent sodium channel function is regulated through membrane mechanics. *Biophys. J.* 1999, 77, 1945–1959. [CrossRef]
137. Agwa, A.J.; Lawrence, N.; Deplazes, E.; Chenave, O.; Chen, R.M.; Craik, D.J.; Schroeder, C.I.; Henriques, S.T. Spider peptide toxin HwTx-IV engineered to bind to lipid membranes has an increased inhibitory potency at human voltage-gated sodium channel hNav1.7. *Biochim. Biophys. Acta* 2017, 1859, 835–844. [CrossRef] [PubMed]
138. Hung, A.; Kuyucak, S.; Schroeder, C.I.; Kaas, Q. Modelling the interactions between animal venom peptides and membrane proteins. *Neuropharmacology* 2017, 127, 20–31. [CrossRef] [PubMed]
139. Agwa, A.J.; Henriques, S.T.; Schroeder, C.I. Gating modifier toxin interactions with ion channels and lipid bilayers: Is the trimolecular complex real? *Neuropharmacology* 2017, 127, 32–45. [CrossRef]
140. Deplazes, E.; Henriques, S.T.; Smith, J.J.; King, G.F.; Craik, D.J.; Mark, A.E.; Schroeder, C.I. Membrane-binding properties of gating modifier and pore-blocking toxins: Membrane interaction is not a prerequisite for modification of channel gating. *Biochim. Biophys. Acta* 2016, 1858, 872–882. [CrossRef]
141. Flinspach, M.; Xu, Q.; Piekacz, A.; Fellows, R.; Hagan, R.; Gibbs, A.; Liu, Y.; Neff, R.; Friedman, J.; Eckert, W. Insensitivity to pain induced by a potent selective closed-state Nav1.7 inhibitor. *Sci. Rep.* 2017, 7, 39662. [CrossRef]
142. Revell, J.D.; Lund, P.-E.; Linley, J.E.; Metcalfe, J.; Burmeister, N.; Sridharan, S.; Jones, C.; Jermutus, L.; Bednarek, M.A. Potency optimization of Huwentoxin-IV on hNav1.7: A neurotoxin TTX-S sodium-channel antagonist from the venom of the Chinese bird-eating spider *Selenocosmia huwena*. *Peptides* 2013, 44, 40–46. [CrossRef]
143. Rahnama, S.; Deuis, J.R.; Cardoso, F.C.; Ramanujam, V.; Lewis, R.J.; Rash, L.D.; King, G.F.; Vetter, I.; Mobli, M. The structure, dynamics and selectivity profile of a Na\textsubscript{V,1.7} potency-optimised huwentoxin-IV variant. *PLoS ONE* 2017, 12, e0173551. [CrossRef]

144. Shcherbatko, A.; Rossi, A.; Foletti, D.; Zhu, G.; Bogin, O.; Galindo Casas, M.; Rickert, M.; Hasa-Moreno, A.; Bartsevich, V.; Crameri, A.; et al. Engineering highly potent and selective microproteins against Na\textsubscript{V,1.7} sodium channel for treatment of Pain. *J. Biol. Chem.* 2016, 291, 13974–13986. [CrossRef]

145. Li, D.; Xiao, Y.; Hu, W.; Xie, J.; Bosmans, F.; Tytgat, J.; Liang, S. Function and solution structure of hainantoxin-I, a novel insect sodium channel inhibitor from the Chinese bird spider *Selenocosmia hainana*. *FEBS Lett.* 2003, 555, 616–622. [CrossRef]

146. Mueller, A.; Starobova, H.; Morgan, M.; Dekan, Z.; Cheneval, O.; Alewood, P.F.; Deuis, J.R.; Vetter, I. Anti-allodynic effects of the selective Na\textsubscript{V,1.7} inhibitor Pn3a in a mouse model of acute post-surgical pain: Evidence for analgesic synergy with opioids and baclofen. *Pain* 2019, 160, 1766–1780. [CrossRef] [PubMed]

147. Peigneur, S.; Paiva, A.; Cordeiro, M.; Borges, M.; Diniz, M.; de Lima, M.; Tytgat, J. Voltage-gated sodium channels and pain-related disorders. *Ann. Neurol.* 2010, 67, 26–39. [CrossRef] [PubMed]

148. Bosmans, F.; Martin-Eauclaire, M.-F.; Swartz, K.J. Deconstructing voltage sensor function and pharmacology in sodium channels. *Nature* 2008, 456, 202–208. [CrossRef] [PubMed]

149. Xiao, Y.; Jackson, J.O.; Liang, S.; Cummins, T.R. Common molecular determinants of tarantula huwentoxin-IV expression and alleviation of neuropathic pain by regulating voltage-gated sodium channel Na\textsubscript{V,1.3} in Rats. *Front. Mol. Neurosci.* 2017, 10, 126. [CrossRef] [PubMed]

150. Bosmans, F.; Milescu, M.; Swartz, K.J. Palmitoylation influences the function and pharmacology of sodium channels. *Proc. Natl. Acad. Sci. USA* 2011, 108, 20213–20218. [CrossRef]

151. Kanellopoulos, A.H.; Matsuyama, A. Voltage-gated sodium channels and pain-related disorders. *Clin. Sci. (Lond.)* 2016, 130, 2257–2265. [CrossRef]

152. Dib-Hajj, S.D.; Geha, P.; Waxman, S.G. Sodium channels in pain disorders: Pathophysiology and prospects for treatment. *Pain* 2017, 158 (Suppl. 1), s97–s107. [CrossRef]

153. Vetter, I.; Deuis, J.R.; Mueller, A.; Israel, M.R.; Starobova, H.; Zhang, A.; Rash, L.D.; Mobli, M. Na\textsubscript{V,1.7} as a pain target—from gene to pharmacology. *Pharmacol. Ther.* 2017, 172, 73–100. [CrossRef]

154. Dib-Hajj, S.D.; Cummins, T.R.; Black, J.A.; Waxman, S.G. Sodium channels in normal and pathological pain. *Annu. Rev. Neurosci.* 2010, 33, 325–347. [CrossRef]

155. Leipold, E.; Liebmann, L.; Korenke, G.C.; Heinrich, T.; Giesselmann, S.; Baets, J.; Ebbinghaus, M.; Goral, R.O.; Stodberg, T.; Hennings, J.C.; et al. *A de novo* gain-of-function mutation in SCN11A causes loss of pain perception. *Nat. Genet.* 2018, 45, 1399–1404. [CrossRef]

156. Chen, H.P.; Zhou, W.; Kang, I.M.; Yan, H.; Zhang, L.; Xu, B.H.; Cai, W.H. Intrathecal miR-96 inhibits Na\textsubscript{V,1.3} expression and alleviates neuropathic pain in rat following chronic constriction injury. *Neurochem. Res.* 2014, 39, 76–83. [CrossRef] [PubMed]

157. Su, S.; Shao, J.; Zhao, Q.; Ren, X.; Cai, W.; Li, L.; Bai, Q.; Chen, X.; Xu, B.; Wang, J.; et al. MiR-30b Ameliorates neuropathic pain by regulating voltage-gated sodium channel Na\textsubscript{V,1.3} in Rats. *Front. Mol. Neurosci.* 2017, 10, 126. [CrossRef] [PubMed]

158. Faber, C.G.; Hoeijmakers, J.G.; Ahn, H.S.; Cheng, X.; Han, C.; Choi, J.S.; Estacion, M.; Lauria, G.; Vanhoutte, E.K.; Gerrits, M.M.; et al. Gain of function Na\textsubscript{V,1.7} mutations in idiopathic small fiber neuropathy. *Ann. Neurol.* 2012, 71, 26–39. [CrossRef] [PubMed]

159. Dib-Hajj, S.D.; Black, J.A.; Waxman, S.G. Voltage-gated sodium channels: Therapeutic targets for pain. *Pain Med.* 2009, 10, 1260–1269. [CrossRef]

160. Deuis, J.R.; Zimmermann, K.; Romanovsky, A.A.; Possani, L.D.; Cabot, P.J.; Lewis, R.J.; Vetter, I. An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Na\textsubscript{V,1.6} in peripheral pain pathways. *Pain* 2013, 154, 1749–1757. [CrossRef]

161. Qin, S.; Jiang, F.; Zhou, Y.; Zhou, G.; Ye, P.; Ji, Y. Local knockdown of Na\textsubscript{V,1.6} relieves pain behaviors induced by BmK I. *Acta Biochim. Biophys. Sin.* 2017, 49, 713–721. [CrossRef]

162. Zhao, P.; Barr, T.P.; Hou, Q.; Dib-Hajj, S.D.; Black, J.A.; Albrect, P.J.; Petersen, K.; Eisenberg, E.; Wymer, J.P.; Rice, F.L.; et al. Voltage-gated sodium channel expression in rat and human epidermal keratinocytes: Evidence for a role in pain. *Pain* 2008, 139, 90–105. [CrossRef]
163. Catterall, W.A.; Goldin, A.L.; Waxman, S.G. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev. 2005, 57, 397–409. [CrossRef]

164. Erickson, A.; Deiteren, A.; Harrington, A.M.; Garcia-Caraballo, S.; Castro, J.; Caldwell, A.; Grundy, L.; Brierley, S.M. Voltage-gated sodium channels: (NaV)1.1 ligating the field to determine their contribution to visceral nociception. J. Physiol. 2018, 596, 785–807. [CrossRef]

165. Black, J.A.; Dib-Hajj, S.; McNabola, K.; Jeste, S.; Rizzo, M.A.; Kocsis, J.D.; Waxman, S.G. Spinal sensory neurons express multiple sodium channel α-subunit mRNAs. Brain Res. Mol. Brain Res. 1996, 43, 117–131. [CrossRef]

166. Wang, W.; Gu, J.; Li, Y.Q.; Tao, Y.X. Are voltage-gated sodium channels on the dorsal root ganglion involved in the development of neuropathic pain? Mol. Pain 2011, 7, 16. [CrossRef] [PubMed]

167. Fukuoka, T.; Kobayashi, K.; Yamanaka, H.; Obata, K.; Dai, Y.; Noguchi, K. Comparative study of the distribution of the α-subunits of voltage-gated sodium channels in normal and axotomized rat dorsal root ganglion neurons. J. Comp. Neurol. 2008, 510, 188–206. [CrossRef] [PubMed]

168. Hockley, J.R.; González-Cano, R.; McMurray, S.; Tejada-Giraldez, M.A.; McGuire, C.; Torres, A.; Wilbrey, A.L.; Cibert-Gotón, V.; Nieto, F.R.; Pitcher, T. Visceral and somatic pain modalities reveal NaV1.7-independent visceral nociceptive pathways. J. Physiol. 2017, 595, 2661–2679. [CrossRef] [PubMed]

169. Jay Gargus, J.; Tournay, A. Novel mutation confirms seizure locus SCN1A is also FHM3 migraine locus. Pediatr. Neurol. 2007, 37, 407–410. [CrossRef] [PubMed]

170. Bosmans, F.; Kalia, J. Derivatives of rufinamide and their use in inhibition of the activation of human voltage-gated sodium channels. US Patent 9,771,335, 26 September 2017.

171. Gilchrist, J.; Dutton, S.; Diaz-Bustamante, M.; McPherson, A.; Olivares, N.; Kalia, J.; Escayg, A.; Bosmans, F. NaV1.1 modulation by a novel triazole compound attenuates epileptic seizures in rodents. ACS Chem. Biol. 2014, 9, 1204–1212. [CrossRef] [PubMed]

172. Suter, M.R.; Kirschmann, G.; Laedermann, C.J.; Abriel, H.; Decosterd, I. Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology 2013, 118, 160–172. [CrossRef]

173. Cummins, T.R.; Aglieco, F.; Renganathan, M.; Herzog, R.I.; Dib-Hajj, S.D.; Waxman, S.G. NaV1.3 sodium channels: Rapid repriming and slow closed-state inactivation display quantitative differences after expression in a mammalian cell line and in spinal sensory neurons. J. Neurosci. 2001, 21, 5952–5961. [CrossRef]

174. Erickson, A.; Deiteren, A.; Harrington, A.M.; Garcia-Caraballo, S.; Castro, J.; Caldwell, A.; Grundy, L.; Brierley, S.M. Voltage-gated sodium channels: (NaV)1.1 ligating the field to determine their contribution to visceral nociception. J. Physiol. 2018, 596, 785–807. [CrossRef]

175. Black, J.A.; Dib-Hajj, S.; McNabola, K.; Jeste, S.; Rizzo, M.A.; Kocsis, J.D.; Waxman, S.G. Spinal sensory neurons express multiple sodium channel α-subunit mRNAs. Brain Res. Mol. Brain Res. 1996, 43, 117–131. [CrossRef]

176. Black, J.A.; Nikolajsen, L.; Kroner, K.; Jensen, T.S.; Waxman, S.G. Multiple sodium channel isoforms and neuropathic pain behavior in rats. Pain 2005, 117, 145–153. [CrossRef]

177. Jay Gargus, J.; Tournay, A. Novel mutation confirms seizure locus SCN1A is also FHM3 migraine locus. Pediatr. Neurol. 2007, 37, 407–410. [CrossRef] [PubMed]

178. Hains, B.C.; Saab, C.Y.; Klein, J.P.; Craner, M.J.; Waxman, S.G. Altered sodium channel expression in second-order spinal sensory neurons contributes to pain after peripheral nerve injury. J. Neurosci. 2004, 24, 4832–4839. [CrossRef]
182. Xu, W.; Zhang, J.; Wang, Y.; Wang, L.; Wang, X. Changes in the expression of voltage-gated sodium channels Nav1.3, Nav1.7, Nav1.8, and Nav1.9 in rat trigeminal ganglia following chronic constriction injury. *Neuroreport* 2016, 27, 929–934. [CrossRef]

183. Black, J.A.; Liu, S.; Tanaka, M.; Cummins, T.R.; Waxman, S.G. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. *Pain* 2004, 108, 237–247. [CrossRef]

184. O’Brien, J.E.; Meisler, M.H. Sodium channel SCN8A (Nav1.6): Properties and de novo mutations in epileptic encephalopathy and intellectual disability. *Front. Genet.* 2013, 4, 213. [CrossRef] [PubMed]

185. Black, J.A.; Renganathan, M.; Waxman, S.G. Sodium channel Na\textsubscript{v}1.3 in dorsal root ganglia of STZ-induced diabetic rats alleviates tactile allodynia. *Mol. Med.* 2015, 21, 544–552. [CrossRef]

186. Grasso, G.; Landi, A.; Alafaci, C. A novel pathophysiological mechanism contributing to trigeminal neuralgia. *Brain Res. Mol. Brain Res.* 2012, 173, 1–14. [CrossRef] [PubMed]

187. Nassar, M.A.; Baker, M.D.; Levato, A.; Ingram, R.; Mallucci, G.; McMahon, S.B.; Wood, J.N. Nerve injury induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice. *Mol. Pain* 2006, 2, 33. [CrossRef] [PubMed]

188. O’Brien, J.E.; Meisler, M.H. Sodium channel SCN8A (Nav1.6): Properties and de novo mutations in epileptic encephalopathy and intellectual disability. *Front. Genet.* 2013, 4, 213. [CrossRef] [PubMed]

189. Black, J.A.; Liu, S.; Tanaka, M.; Cummins, T.R.; Waxman, S.G. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. *Pain* 2004, 108, 237–247. [CrossRef]

190. Ramachandra, R.; Elmslie, K.S. EXPRESS: Voltage-dependent sodium (Nav) channels in group IV sensory afferents. *Mol. Pain* 2016, 12. [CrossRef]

191. Persson, A.K.; Black, J.A.; Gasser, A.; Cheng, X.; Fischer, T.Z.; Waxman, S.G. Sodium-calcium exchanger and multiple sodium channel isoforms in intra-epidermal nerve terminals. *Mol. Pain* 2010, 6, 84. [CrossRef]

192. Kennedy, P.G.; Montague, P.; Scott, F.; Grinfeld, E.; Ashrafi, G.H.; Breuer, J.; Rowan, E.G. *Varicella-zoster* viruses associated with post-herpetic neuralgia induce sodium current density increases in the ND7-23 Nav1.8 neuroblastoma cell line. *PLoS ONE* 2013, 8, e51570. [CrossRef]

193. Ren, Y.-S.; Qian, N.-S.; Tang, Y.; Liao, Y.-H.; Yang, Y.-L.; Dou, K.-F.; Toi, M. Sodium channel Nav1.6 is up-regulated in the dorsal root ganglia in a mouse model of type 2 diabetes. *Brain Res. Bull.* 2012, 87, 244–249. [CrossRef]

194. Grasso, G.; Landi, A.; Alafaci, C. A novel pathophysiological mechanism contributing to trigeminal neuralgia. *Brain Res. Mol. Brain Res.* 2012, 173, 1–14. [CrossRef] [PubMed]

195. Xie, W.; Strong, J.A.; Zhang, J.M. Local knockdown of the Nav1.6 sodium channel reduces pain behaviors, sensory neuron excitability, and sympathetic sprouting in rat models of neuropathic pain. *Neuroscience* 2015, 291, 317–330. [CrossRef] [PubMed]

196. Xie, W.; Strong, J.A.; Ye, L.; Mao, J.X.; Zhang, J.M. Knockdown of sodium channel Na\textsubscript{v}1.6 blocks mechanical pain and abnormal bursting activity of afferent neurons in inflamed sensory ganglia. *Pain* 2013, 154, 1170–1180. [CrossRef] [PubMed]

197. Xie, W.; Strong, J.A.; Ye, L.; Mao, J.X.; Zhang, J.M. Knockdown of sodium channel Na\textsubscript{v}1.6 blocks mechanical pain and abnormal bursting activity of afferent neurons in inflamed sensory ganglia. *Pain* 2013, 154, 1170–1180. [CrossRef] [PubMed]

198. Black, J.A.; Frézel, N.; Dib-Hajj, S.D.; Waxman, S.G. Expression of Nav1.7 in DRG neurons extends from peripheral terminals in the skin to central preterminal branches and terminals in the dorsal horn. *Mol. Pain* 2012, 8, 82. [CrossRef] [PubMed]

199. Rush, A.M.; Cummins, T.R.; Waxman, S.G. Multiple sodium channels and their roles in electrogenesis within dorsal root ganglion neurons. *J. Physiol.* 2007, 579, 1–14. [CrossRef]
202. Herzog, R.I.; Cummins, T.R.; Ghassemi, F.; Dib-Hajj, S.D.; Waxman, S.G. Distinct repriming and closed-state inactivation kinetics of Nav1.6 and Nav1.7 sodium channels in mouse spinal sensory neurons. J. Physiol. 2003, 551, 741–750. [CrossRef]

203. Fertleman, C.R.; Baker, M.D.; Parker, K.A.; Moffatt, S.; Elmslie, F.V.; Abrahamsen, B.; Ostman, J.; Klugbauer, N.; Wood, J.N.; Gardiner, R.M.; et al. SCN9A mutations in paroxysmal extreme pain disorder: Allelic variants underlie distinct channel defects and phenotypes. Neuron 2006, 52, 767–774. [CrossRef]

204. Blair, N.T.; Bean, B.P. Roles of tetrodotoxin (TTX)-sensitive Na\(^+\) currents in human dorsal root ganglion neurons. FEBS Lett. 1999, 462, 117–120. [CrossRef]

205. Akopian, A.N.; Sivilotti, L.; Wood, J.N. A tetrodotoxin-resistant voltage-gated sodium channel expressed in mouse ciliary ganglia. J. Physiol. 1999, 518, 193–199. [CrossRef] [PubMed]

206. Ribbons, D.W.; Black, J.A.; Waxman, S.G. Molecular identities of two tetrodotoxin-resistant sodium channels in corneal axons. Exp. Eye Res. 2002, 75, 193–199. [CrossRef] [PubMed]

207. Dib-Hajj, S.D.; Tyrrell, L.; Cummins, T.R.; Black, J.A.; Wood, P.M.; Waxman, S.G. Two tetrodotoxin-resistant sodium channels in human dorsal root ganglion neurons. FEBS Lett. 1999, 462, 117–120. [CrossRef]

208. Black, J.A.; Waxman, S.G. Molecular identities of two tetrodotoxin-resistant sodium channels in corneal axons. J. Physiol. 1999, 518, 193–199. [CrossRef] [PubMed]

209. Dib-Hajj, S.D.; Tyrrell, L.; Cummins, T.R.; Black, J.A.; Wood, P.M.; Waxman, S.G. Two tetrodotoxin-resistant sodium channels in human dorsal root ganglion neurons. FEBS Lett. 1999, 462, 117–120. [CrossRef]

210. Tan, Z.-Y.; Piekacz, A.D.; Priest, B.T.; Knopp, K.L.; Krajewski, J.L.; McDermott, J.S.; Nisenbaum, E.S.; Cummins, T.R. Tetrodotoxin-resistant sodium channels in sensory neurons generate slow resurgent currents that are enhanced by inflammatory mediators. J. Neurosci. 2014, 34, 7190–7197. [CrossRef] [PubMed]

211. Yang, Y.; Wang, Y.; Li, S.; Xu, Z.; Li, H.; Ma, L.; Fan, J.; Bu, D.; Liu, B.; Fan, Z.; et al. Mutations in SCN9A, encoding a sodium channel α subunit, in patients with primary erythermalgia. J. Med. Genet. 2004, 41, 171–174. [CrossRef]

212. Blair, N.T.; Bean, B.P. Roles of tetrodotoxin (TTX)-sensitive Na\(^+\) currents in the action potentials of nociceptive sensory neurons following axotomy. J. Neurosci. 2002, 22, 10277–10290. [CrossRef]

213. Leyton, G.; Shimojo, T.; Dib-Hajj, S.D.; Black, J.A.; Waxman, S.G. Down-regulation of transcripts for Na channel α-SNS in spinal cord dorsal root ganglia neurons and their role in colitis-induced hyperexcitability. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287, G845–G855. [CrossRef]

214. Yu, Y.; Zhao, F.; Guan, S.-M.; Chen, J. Antisense-mediated knockdown of Nav1.8, but not Nav1.9, generates inhibitory effects on complete Freund’s adjuvant-induced inflammatory pain in rat. PLoS ONE 2011, 6, e19865. [CrossRef] [PubMed]

215. Lin, Y.-M.; Fu, Y.; Winston, J.; Radhakrishnan, R.; Sarna, S.K.; Huang, L.-Y.M.; Shi, X.-Z. Pathogenesis of abdominal pain in bowel obstruction: Role of mechanical stress-induced upregulation of nerve growth factor in gut smooth muscle cells. Pain 2017, 158, 583–592. [CrossRef] [PubMed]

216. Dib-Hajj, S.; Black, J.; Felts, P.; Waxman, S. Down-regulation of transcripts for Na channel α-SNS in spinal sensory neurons following axotomy. Proc. Natl. Acad. Sci. USA 1996, 93, 14950–14954. [CrossRef] [PubMed]

217. Cummins, T.R.; Waxman, S.G. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. J. Neurosci. 1997, 17, 3503–3514. [CrossRef]

218. Decosterd, I.; Ji, R.-R.; Abdil, S.; Tate, S.; Wolff, C.J. The pattern of expression of the voltage-gated sodium channels Na\(_{\text{V}}\)1.8 and Na\(_{\text{V}}\)1.9 does not change in uninjured primary sensory neurons in experimental neuropathic pain models. Pain 2002, 96, 269–277. [CrossRef]
Toxins 2019, 11, 626

222. Gold, M.S.; Weinreich, D.; Kim, C.-S.; Wang, R.; Treanor, J.; Porreca, F.; Lai, J. Redistribution of Nav\textsubscript{1.8} in uninjured axons enables neuropathic pain. J. Neurosci. 2003, 23, 158–166. [CrossRef]

223. Zhang, X.-F.; Zhu, C.Z.; Thimmapaya, R.; Choi, W.S.; Honore, P.; Scott, V.E.; Kroeger, P.E.; Sullivan, J.P.; Faltynek, C.R.; Gopalakrishnan, M. Differential action potentials and firing patterns in injured and uninjured small dorsal root ganglion neurons after nerve injury. Brain Res. 2004, 1009, 147–158. [CrossRef]

224. Faber, C.G.; Lauria, G.; Merkies, I.S.; Cheng, X.; Han, C.; Ahn, H.S.; Persson, A.K.; Hooijmakers, J.G.; Gerrits, M.M.; Pierro, T.; et al. Gain-of-function Nav\textsubscript{1.8} mutations in painful neuropathy. Proc. Natl. Acad. Sci. USA 2012, 109, 19444–19449. [CrossRef]

225. Dib-Hajj, S.D.; Tyrrell, L.; Black, J.A.; Waxman, S.G. NaN, a novel voltage-gated Na channel, is expressed preferentially in peripheral sensory neurons and down-regulated after axotomy. Proc. Natl. Acad. Sci. USA 1998, 95, 8963–8968. [CrossRef]

226. Rugiero, F.; Mistry, M.; Sage, D.; Black, J.A.; Waxman, S.G.; Crest, M.; Clerc, N.; Delmas, P.; Gola, M. Selective expression of a persistent tetrodotoxin-resistant Na\textsuperscript{+} current and Nav\textsubscript{1.9} subunit in myenteric sensory neurons. J. Neurosci. 2003, 23, 2715–2725. [CrossRef]

227. Cummins, T.R.; Dib-Hajj, S.D.; Black, J.A.; Akopian, A.N.; Wood, J.N.; Waxman, S.G. A novel persistent tetrodotoxin-resistant sodium current in SNS-null and wild-type small primary sensory neurons. J. Neurosci. 1999, 19, RC43. [CrossRef] [PubMed]

228. Herzog, R.; Cummins, T.; Waxman, S. Persistent TTX-resistant Na\textsuperscript{+} current affects resting potential and response to depolarization in simulated spinal sensory neurons. J. Neurophysiol. 2001, 86, 1351–1364. [CrossRef] [PubMed]

229. Maingret, F.; Coste, B.; Padilla, F.; Clerc, N.; Crest, M.; Korogod, S.M.; Delmas, P. Inflammatory mediators increase Nav\textsubscript{1.9} current and excitability in nociceptors through a coincident detection mechanism. J. Gen. Physiol. 2008, 131, 211–225. [CrossRef] [PubMed]

230. Priest, B.T.; Murphy, B.A.; Lindia, J.A.; Diaz, C.; Abbadi, C.; Ritter, A.M.; Liberator, P.; Iyer, L.M.; Kash, S.F.; Kohler, M.G.; et al. Contribution of the tetrodotoxin-resistant voltage-gated sodium channel Nav\textsubscript{1.9} to sensory transmission and nociceptive behavior. Proc. Natl. Acad. Sci. USA 2005, 102, 9382–9387. [CrossRef] [PubMed]

231. Amaya, F.; Wang, H.; Costigan, M.; Alchornie, A.J.; Hatcher, J.P.; Egerton, J.; Stein, T.; Morisset, V.; Grose, D.; Gunthorpe, M.J.; et al. The voltage-gated sodium channel Nav\textsubscript{1.9} is an effector of peripheral inflammatory pain hypersensitivity. J. Neurosci. 2006, 26, 12852–12860. [CrossRef] [PubMed]

232. Lolignier, S.; Amsalem, M.; Maingret, F.; Padilla, F.; Gabriac, M.; Chapuy, E.; Eschalier, A.; Delmas, P.; Busslerolles, J. Nav\textsubscript{1.9} channel contributes to mechanical and heat pain hypersensitivity induced by subacute and chronic inflammation. PLoS ONE 2011, 6, e23083. [CrossRef]

233. Zhang, X.Y.; Wen, J.; Yang, W.; Wang, C.; Gao, L.; Zheng, L.H.; Wang, T.; Ran, K.; Li, Y.; Li, X.; et al. Gain-of-function mutations in SCN11A cause familial episodic pain. J. Hum. Genet. 2013, 93, 957–966. [CrossRef]

234. Han, C.; Yang, Y.; de Grief, B.T.A.; Hooijmakers, J.G.J.; Gerrits, M.M.; Verhamme, C.; Qu, J.; Lauria, G.; Merkies, I.S.J.; Faber, C.G.; et al. The domain II S4-S5 linker in Nav\textsubscript{1.9} activation, impairs fast inactivation, and produces human painful neuropathy. Neuromol. Med. 2015, 17, 158–169. [CrossRef]

235. Huang, J.; Han, C.; Estacion, M.; Vasyllyev, D.; Hooijmakers, J.G.; Gerrits, M.M.; Tyrrell, L.; Lauria, G.; Faber, C.G.; Dib-Hajj, S.D.; et al. Gain-of-function mutations in sodium channel Nav\textsubscript{1.9} in painful neuropathy. Brain 2014, 137, 1627–1642. [CrossRef]

236. Bosmans, F.; Puopolo, M.; Martin-Eauclaire, M.F.; Bean, B.P.; Swartz, K.J. Functional properties and toxin pharmacology of a dorsal root ganglion sodium channel viewed through its voltage sensors. J. Gen. Physiol. 2011, 138, 59–72. [CrossRef]

237. Gonçalves, T.C.; Boukaila, R.; Molgó, J.; Amar, M.; Partiseti, M.; Servent, D.; Benoit, E. Direct evidence for high affinity blockade of Nav\textsubscript{1.6} channel subtype by huwentoxin-IV spider peptide, using multiscale functional approaches. Neuropharmacology 2018, 133, 404–414. [CrossRef] [PubMed]

238. Zhang, Y.; Yang, Q.; Zhang, Q.; Peng, D.; Chen, M.; Liang, S.; Zhou, X.; Liu, Z. Engineering gain-of-function analogues of the spider venom peptide HNTX-I, a potent blocker of the hNav\textsubscript{1.7} sodium channel. Toxins 2018, 10, 358. [CrossRef] [PubMed]
239. Cherki, R.S.; Kolb, E.; Langut, Y.; Tsveyer, L.; Bajayo, N.; Meir, A. Two tarantula venom peptides as potent and differential Nav channels blockers. *Toxicon* 2014, 77, 58–67. [CrossRef] [PubMed]

240. Chow, C.Y.; Cristofori-Armstrong, B.; Undheim, E.A.; King, G.F.; Rash, L.D. Three peptide modulators of the human voltage-gated sodium channel 1.7, an important analgesic target, from the venom of an Australian tarantula. *Toxins* 2015, 7, 2494–2513. [CrossRef]

241. Redaelli, E.; Cassulini, R.R.; Silva, D.F.; Clement, H.; Schiavon, E.; Zamudio, F.Z.; Odell, G.; Arcangeli, A.; Clare, J.J.; Alagón, A. Target promiscuity and heterogeneous effects of tarantula venom peptides affecting Na\(^+\) and K\(^+\) ion channels. *J. Biol. Chem.* 2010, 285, 4130–4142. [CrossRef]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).